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EXECUTIVE SUMMARY
It is estimated that between 11'000 and 21'000 individuals are living with HIV infection in
Switzerland1. Compared to the early years of the epidemic, the number of new cases has
decreased and more potent drugs are available. In such a changing context, disposing of
pertinent information is important to target the fight against HIV infection as effectively as
possible. Social cost is one example of such information. Indeed, assessing the social cost of
HIV, its different components and their relative importance  is a central element in designing
public health policies and identifying priorities. Assessing the social cost enables various
comparisons, for instance, between prevention and treatment costs, or an assessment of the
cost impact of Highly Active Antiretroviral Therapy (HAART). Comparisons with the social
cost of other illnesses or the assessment of HIV infection in the total Swiss health care costs
are also relevant elements for decision makers.
· Objectives:
 The objective of the present study is to assess the social cost of HIV infection in Switzerland.
For that purpose, we consider, in the first part of the report, a “Bottom-Up” model. Under this
approach, the various components of the social cost are first estimated separately and
compared, and then reassembled.
 
 As anticipation of future costs is an issue of importance to health decision makers in terms of
long term strategy, we consider, in the second part, future HIV social cost. The ongoing
changes and progresses over the last ten years demonstrate that long term projections would
be hazardous, so we focus on a short time span and assess social cost for the years 2001 and
2005.
 
· Methodology:
 The assessment of HIV social cost in 1998 relies on a “Bottom-Up” model that aggregates  the
different components of the social cost. Our assessment of social cost focuses on two main
components, i.e., HIV direct and indirect costs. Direct costs are divided into outpatient and
inpatient care costs. Outpatient care comprises drug treatments, ambulatory medical
visits, psychotherapy, and home care. Inpatient care relates to hospital and institutional
psycho-social care. Indirect costs are associated with HIV morbidity and mortality.  Since
methodologies for estimating intangible costs are quite complex to implement and the results
often difficult to interpret, particularly in a context of ongoing changes as is the case for HIV,
such costs have not been included in our study. The issue of whether prevention costs should
be included or not in the social cost is still the object of a debate among health economists.
Although we do not consider prevention costs as a component of the social cost, we do
compare these costs in our study with social cost components.
 
 To perform projections of future HIV social cost, we develop a multistate Markov model
describing HIV patients’ transition between different health states over time. A cost (direct and
indirect) per unit time is defined for each health state. To determine future social cost, the
expected time spent by individuals in each health state is multiplied by the costs associated with
the corresponding health state.
 
                                                 
1 Office Fédéral de la Santé Publique (1999),SIDA et VIH en Suisse : Situation épidémiologique à la fin 1998,
   Berne
· Results:
We initially undertake an assessment of prevention costs. Our estimate of HIV prevention
costs at the Swiss level for the year 1998 ranges from 41 to 62 million Sfr.  Despite the fact
that we concentrate only on the main prevention programmes, the above figures demonstrate
that HIV prevention expenses are quite substantial.
We then concentrate on HIV direct costs, evaluated at 168 million Sfr. and displayed in Table
A. One central result is the importance of tiretroviral costs, estimated at 91 million Sfr.,
and accounting for more than  50 % of total direct costs. Prior to the introduction of Highly
Active Antiretroviral Therapy (HAART), hospital care costs represented the main share of
direct costs. Since then, hospitalisation cost share has declined and represented in 1998 19 %
of total direct costs, i.e.,  32 million Sfr.
Table  A : Social Cost components
Cost components Costs (Sfr.) Percentage
       OUTPATIENT CARE
HIV related drug treatments
    Anti-retroviral drugs       91’400’000    54 %
    Co-morbidity drugs         9'140’000      6 %
    Co-medication         2’920’000      2 %
Medical and Para-Medial Care
    Ambulatory medical visits       24’000’000    14 %
    Psychotherapy         2’350’000      1 %
    Home care         1’780’000      1 %
      TOTAL OUTPATIENT CARE            131’590’000     78 %
      INPATIENT CARE
Hospital care       32'290’000     19 %
Institutional psycho-social care         4’300’000       3 %
    TOTAL INPATIENT CARE              36’590’000     22 %
TOTAL DIRECT COSTS            168’180’000          100 %
    MORBIDITY COSTS            115’100’000          41.8 %
    MORTALITY COSTS            160’040’000          58.2 %
TOTAL INDIRECT COSTS            275’140’000         100 %
SOCIAL COST            443’310’000
We furthermore examine indirect costs, i.e., morbidity and mortality costs associated with HIV
infection, and adopt the “human capital” approach to evaluate them. Productivity losses
associated with HIV morbidity are estimated at 115 million Sfr. in 1998, whereas mortality
costs are evaluated at 160 million Sfr.  
HIV social cost (direct + indirect costs) is estimated at 443 million  Sfr. in Switzerland for the
year 1998. Alternative assumptions, reflecting either more or less conservative views, are  also
considered,  and result in a social cost of 367 and 586 million Sfr., respectively.
The annual cost per patient is high, 21’000 Sfr and 14’400 Sfr for direct and morbidity costs,
respectively. Furthermore, since HIV infection affects relatively young people, average cost
per death due to AIDS is one of the highest among all causes of death.  HIV infection cannot,
therefore, be neglected within the frame of public health policy. This is particularly true within
the current context suggesting a certain disregard of HIV prevention messages.
In the second part of the report, we project social cost for the years 2001 and 2005. On the
one hand, the annual direct and indirect cost per patient is expected to slightly decrease in the
forthcoming years. On the other hand, the rise in the number of individuals living with HIV
infection will favour an increase of the social cost. On the basis of our assumptions, the cost
reduction per patient will not outweigh the cost increase resulting from the greater number of
HIV patients. Therefore, total HIV social cost is expected to rise in forthcoming years, from
443 million Sfr. in 1998 to  542 million Sfr. in 2005, corresponding to an annual growth rate
of approximately 3 %. Different elements, however, could modify these conclusions. First, a
change in the price of antiretroviral drugs would have a significant effect on social cost, since
they represent the main direct cost component. Second, new therapeutic options could be
developed in a near future, namely intermittent antiretroviral drug treatments, which would
reduce antiretroviral drug consumption. Third, one could anticipate an increase in the number
of hospitalisations due to treatment side-effects, in relation to longer-lasting antiretroviral
treatments. Finally, our projections assume a constant number of new HIV cases in the
forthcoming years, however, a substantial change in their number would also affect our
projections.
Our projections suggest that HIV prevention should remain a key element in the battle against
HIV as it constitutes an essential means to limit or reduce the HIV social cost over the next
years.
PART I: HIV SOCIAL COST IN 1998
INTRODUCTION
Since 1981, when scientists in the United States reported the first clinical evidence of a disease
that would become known as AIDS, the HIV2 pidemic has spread to every corner of the
world, and over 36 million people today are infected with HIV3. The rapid development of the
HIV epidemic, the severity of the disease, and the initial lack of effective medicine all explain
that HIV infection became a high priority for decision makers.
It is estimated that between 11'000 and 21'000 individuals are living with HIV infection in
Switzerland4. Compared to the early years of the epidemic, the number of new cases has
decreased and more potent drugs are available. In such a changing context, disposing of
pertinent information is important to target the fight against HIV infection as effectively as
possible. Social cost is one example of such information. Indeed, assessing the social cost of
HIV, its different components and their relative importance  is a central element in designing
public health policies and identifying priorities. Assessing the social cost enables various
comparisons, for instance, between prevention and treatment costs, or an assessment of the
cost impact of Highly Active Antiretroviral Therapy (HAART). Comparisons with the social
cost of other illnesses or the assessment of HIV infection in the total Swiss health care costs
are also relevant elements for decision makers.
The objective of this first part of the report is to assess the social cost of HIV infection in
Switzerland during the year 1998. For that purpose, we consider a “Bottom-Up” model. Under
this approach, the various components of the social cost are first estimated separately and
compared, and then reassembled.
Since HIV epidemiological elements are central to the assessment of the social cost, we
present, in the first chapter, a general overview of HIV epidemiology in Switzerland, and focus
in particular on HIV and AIDS prevalence, HIV and AIDS incidence, and AIDS mortality.
A general description of the “bottom-up model” is presented in the second chapter. The
various cost components of the social cost are detailed. Two main cost categories are
differentiated, i.e., direct and indirect costs. Direct costs relate to inpatient and outpatient care
associated with HIV infection. Indirect costs are associated with HIV morbidity and mortality.
In addition, we also include prevention in our cost assessment. Our different sources of
information are also presented in this chapter. Intangible costs are not included.
An assessment of prevention costs is proposed in the third chapter. The issue of whether
prevention costs should be included or not in the social cost i  still the object of a debate
among health economists. Although we do not consider prevention costs as a component of
the social cost, we include these costs in our study so that they can be compared with social
                                                 
2 HIV is the virus that causes AIDS
3 UNAIDS (2001), Twenty years of HIV/AIDS, Fact-Sheets, Geneva
4 Office Fédéral de la Santé Publique (1999), SIDA et VIH en Suisse: Situation épidémiologique à la fin 1998,
   Berne
cost components. We concentrate on the main programmes related to HIV prevention and
differentiate between primary and secondary prevention.
Direct costs are assessed in the fourth chapter. Direct costs are divided into outpatient and
inpatient care costs. Outpatient care comprises drug treatments, ambulatory medical visits,
psychotherapy, and home care. Inpatient care relates to hospital and institutional psycho-social
care. The methodology adopted to assess direct costs attributable to HIV infection is detailed.
In chapter five, indirect costs are measured. Assessing indirect costs requires the evaluation of
morbidity and mortality costs. Morbidity and mortality costs represent the value of goods and
services that HIV positive individuals would have produced had they not contracted the
disease. We adopted the human capital approach to assess indirect costs. Under the human
capital approach, assessing morbidity costs involve estimating lost workdays attributable to
HIV infection, and then applying an economic value to these workdays. Mortality cost
measurement combines the number of deaths caused by AIDS and an economic value for each
potential year of life lost.
1  HIV EPIDEMIOLOGY IN SWITZERLAND
A general overview of HIV epidemiology in Switzerland is presented in this chapter. We define
the HIV infection as encompassing all disease stages, i.e., AIDS and non-AIDS stages. The
AIDS stage is defined by specific clinical events that are detailed in Appendix 1.
We consider the following epidemiological elements:
· HIV and AIDS incidence
· HIV and AIDS prevalence
· AIDS mortality
 
 The major source of information about new HIV infections and AIDS cases is provided by
anonymous reporting to the Swiss Federal Office of Public Health (SFOPH). This reporting
system is mandatory since December 1987. Additional sources of information reported by the
SFOPH are:
 
 (i) The national death registry
 (ii) Anonymous HIV testing centres
 (iii) Blood transfusion centres
 (iv) Follow up of patients with sexually transmitted diseases
 
 As we shall see below, HIV epidemiology has significantly changed over the last years, with a
significant decrease in the number of new HIV infections and AIDS deaths.
 
 1.1  HIV & AIDS INCIDENCE
 
 The number of yearly diagnosed HIV positive cases provides a good picture of the
epidemiological evolution of HIV infection. Figure 1 indicates the yearly number of new
positive HIV tests declared by confirmation laboratories. Since 1991, there has been an
ongoing decrease, attributable to a large extent to prevention. The number of new cases has
decreased from 2’144 in 1991 to 657 in 1998, i.e., a decrease of 69 %.
 
 Figure 1: Yearly number of new positive HIV tests
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 Source: Office Fédéral de la Santé Publique (1999), SIDA et VIH en Suisse: Situation épidémiologique à la fin
              1998, Berne
 One should however point out that the number of yearly new positive HIV tests does not
exactly correspond to the actual number of new HIV infections. The reasons are the
following:
 
 (i) In general, testing is not done immediately after contracting the disease.
 Thus, positive HIV tests communicated to the SFOPH mainly reflect past
infections. In a context of ongoing decrease in the number of new positive tests,
the number of HIV infections might therefore be overestimated.
 
 (ii) Another element contributing to overestimate the actual number of HIV
infections is the double reporting of new HIV cases, resulting from the
anonymous  report system, and accounting for around 10 to 15 % of reported
HIV confirmation tests5.
 
 (iii) By opposition, the actual number of HIV infections is underestimated by the
fact that a certain proportion of individuals are unaware of being infected. In
France, it was estimated in 19966 that HIV infection had not been detected prior
to AIDS diagnosis in approximately 25% of AIDS cases. Such a phenomenon is
also observed in the Swiss HIV Cohort Study (SHCS). Indeed, on the average,
since 1993, 16 % of individuals who have developed AIDS had their first
positive HIV test within a period of one month prior to the first AIDS defining
disease.
 
 All in all, taking into account these various factors, the SFOPH estimates that the likely
number of HIV infections for 1998 lies between 600 and 700 cases. This corresponds to an
incidence rate of 13/100'000 for the 13-65 year-old population.
 
 The yearly number of declared AIDS cases is depicted in Figure 2. Up to 1995, the number of
AIDS declarations continuously increased. Thereafter, the number of AIDS notifications fell
regularly, and actually decreased by more than 40 %between 1995 and 1998. This change in
evolution is generally attributed to the introduction of the highly active antiretroviral
therapy (HAART), which has now become the standard of care for persons infected with
HIV in developed countries.
 
 During this last decade, two new classes of drugs - protease inhibitors (PI) and the non-
nucleoside reverse transcriptase inhibitors (NNRTI) – have been developed, in addition to
nucleoside reverse transcriptase inhibitors (NRTI), already prescribed since 1987. HAART
combines three or more different drugs such as two nucleoside reverse transcriptase inhibitors
(NRTI) and a protease inhibitor (PI), or two NRTIs and a non-nucleoside reverse transcriptase
inhibitor (NNRTI).
 
 
 
 
                                                 
 5 Office Fédéral de la Santé Publique (1999), SIDA et VIH en Suisse: Situation épidémiologique fin 1998,
  Berne
 6 Bulletin épidémiologique hebdomadaire (1998), Surveillance du Sida en France, vol. 37 : 157-163, Paris
 Figure 2: Yearly number of AIDS declarations
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 One of the main difficulties in assessing the actual number of new AIDS cases is the reporting
delay7. Taking the latter into consideration, the SFOPH has estimated the number of new
AIDS cases between 275 and 325 for 1998. Reporting delays together with a downward trend
in AIDS cases explain the difference between ne  AIDS cases (275-325 cases) and new
AIDS declarations (426 cases in 1998, according to Figure 2).
 
 
 1.2  HIV & AIDS PREVALENCE
 
 The prevalence of a disease is defined as the proportion of people with the disease at a
specific time8. The prevalence of HIV infection in Switzerland can be estimated by subtracting
the cumulative number of deaths due to AIDS from the cumulative number of HIV diagnoses
communicated to the SFOPH.
 
 For the year 1998, the SFOPH has estimated the number of persons infected with HIV
infection residing in Switzerland to be between 13'000 and 19'000. This number represents a
prevalence rate of 0.35 to 0.51 % of the 15-499 y ars old population. By comparison, this rate
is estimated to be 0.10 % in Germany, 0.23 % in Austria, 0.35 % in Italy and 0.43 in France10.
The estimate of AIDS prevalence is significantly lower. The number of individuals living with
AIDS in Switzerland amounted to 2'000 in 1998 according to the SFOPH .
                                                 
 7 The SFOPH has estimated that, over the last years, 66 % of AIDS cases were reported within one year of the
  diagnosis, 80 % within 2 years and 86 % within 3 years (Office Fédéral de la Santé Publique, (1999), SIDA:
  Tableaux mensuels, Bern)
 8 J. Giesecke, Modern Infectious Disease Epidemiology, Edward Arnold, London, 1994
 9 The range 15-49 years old is the standard one regarding HIV infection
 10 UNAIDS (1999), Epidemiological Fact Sheet on HIV/AIDS, Geneva
  1.3  AIDS MORTALITY
 
 Another major change in the HIV/AIDS epidemiology over the last years in Switzerland is
related to AIDS mortality. Figure 3 depicts the yearly number of deaths of individuals at the
AIDS stage11. This figure clearly shows that there has been a substantial decline in the number
of deaths, from a peak of 686 in 1994 to 147 in 1998. This reduction is associated with the
introduction of HAART.
 
 Figure 3: Number of yearly deaths of individuals at the AIDS stage
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 11 The AIDS mortality statistics of the SFOPH include only deaths of individuals at the AIDS stage. There are
no
   official statistics related to the mortality of positive individuals before they reach the AIDS stage.
  2    BOTTOM-UP MODEL: GENERAL DESCRIPTION
 
 2.1  MAIN ELEMENTS OF THE MODEL
 
 In order to assess the social cost of HIV infection in Switzerland in 1998, we consider a
«Bottom-Up » model of costs. Under this approach, the various components of the social cost
are first estimated separately and compared, and then reassembled. Our assessment is
undertaken from a societal viewpoint, i.e., incorporating all relevant costs regardless of who
incurs them.
 
 The main elements of the model, detailed in Figure 4, are the following:
 
· Prevention costs
 The issue of whether prevention costs should be included or not in the social cost is still an
object of debate among health economists. Although we do not consider prevention costs as a
component of the social cost, we do compare these costs with social cost components.
 
· Direct costs
 Inpatient and outpatient care are the main components of direct costs. The methodology that
we adopt for the assessment of direct costs i  largely based on the approach discussed by Rice
(1966) and Drummond et al. (1997).
 
· Indirect costs
 Indirect costs refer to productivity loss resulting from morbidity or mortality. Our appraisal
relies on the « human capital approach », which places monetary value on healthy time using
market wage and alternative measures (Gold et al.,1996).
 
 
 The issue of intangible costs will not be addressed in our study. Intangible are associated with
uncertainty, pain, and distress due to illness. The methodologies for assessing intangible costs,
that is the methods of revealed preference or contingent valuation, have been discussed by
Johannesson (1996), Drummond et al. (1997), and Donaldson (1993, 1995). They are quite
complex to implement and the results often difficult to interpret, particularly in a context of
ongoing changes as is the case for HIV.
17
 Figure 4 : Cost components and main data sources for the assessment of the social cost attributable to HIV infections in 1998.
SOCIAL COST
   3.  PREVENTION COSTS       4.  DIRECT COSTS        5.  INDIRECT
COSTS
3.1 Primary Prevention 4.1 Outpatient Care  4.2.Inpatient Care 5.1 Morbidity
Source :SFOPH12       
Source : SHCS
4.1.1 Drug Treatments       4.2.1 Hospital Care           SFOS
     Sources : SHCS                Sources CHUV
           Pharma Information      SFOS13        
           
3.2 Secondary Prevention        4.1.2 Medical and Paramedical Care         4.2.2 Psycho-social care         5.2 Mortality
                        Source : Le Soleil Levant             Source : SFOS
              
3.2.1 HIV Screening
         Source : SFOPH                 4.1.2.1  Ambulatory Medical Visits
                   Swiss Red Cross                   Sources : CHUV
        Private Practitioners           
3.2.2 PEP           4.1.2.2   Psychotherapy      
        Sources : CHUV14                               Source : Expert Opinion         
                     SHCS15         4.1.2.3   Home care
                                                 
12 Swiss Federal Office of Public Health
13 Swiss Federal Office of Statistics
14 Centre Hospitalier Universitaire Vaudois
15 Swiss HIV Cohort Study
18
             Source : Home Care Federation        
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 2.2  MAIN DATA SOURCES
 
· Service de la Santé Publique du Canton de Vaud (SSP): data on prevention expenses.
 
· Pharma Information: data on antiretroviral sales in Switzerland.
 
· The Swiss HIV Cohort Study16 (SHCS): data on antiretroviral and HIV co-morbidity
drugs, and on morbidity.
 
· Private practitioners: 
 The following HIV specialist medical doctors have accepted to provide us with data on the
ambulatory costs of their HIV infected patients:
 
 . Dr Joelle Wintsch, Internal medicine,  Geneva
 . Dr Christian Jaccard, Internal medicine, Lausanne
 . Dr Christian Junet, Internal medicine, Geneva
 . Dr René Jaccard, Internal medicine, Zurich
 
· The Centre Hospitalier Universitaire Vaudois (CHUV): data on hospitalisation and
ambulatory costs.
 
· Swiss Federal Offices:
 For data related to: Prevalence - Incidence
 Number of deaths
 Number of hospitalisations
 Prevention and public research expenses
 
· Unpublished data:
 M. Alberti, CHUV: data on HIV and home care
 C. Marzolini, CHUV: data on co-medication
 
· Experts’ opinion:
 The following experts have provided advice on data collection and estimation of various
parameters:
 
 . Dr Martin Postma, Economist, Groningen University, Netherlands
 . Dr Jan Hendricks, Statistician, Nijmegen University, Netherlands
 . Dr Martin Gebhardt, MD (Public Health), SFOPH, Bern
 . Dr C. Jaccard, Internal Medicine, Lausanne
 . Dr R. Jaccard, Internal Medicine, Zurich
 . Dr Amalio Telenti, HIV outpatient clinic, CHUV, Lausanne
 . Dr Gilbert Greub, HIV outpatient  clinic, CHUV, Lausanne
 
 
                                                 
 16 This data base is an ongoing cohort established in 1988 and is the result of the collaboration between the five
    Swiss university hospitals and two cantonal hospitals. There were approximately 4'500 individuals
    under observation in 1998.
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 3   PREVENTION COSTS
 
 In this section, we evaluate HIV prevention costs in Switzerland for the year 1998. Because of
their number and variety, an exhaustive review and cost assessment of all prevention activities
directly or indirectly associated with HIV would be extremely difficult. We therefore
concentrate on the main programmes related to HIV prevention.
 
 We do not consider prevention costs as a part of the social cost, but in order to allow a cost
comparison between the latter and the social cost components, we have included in this study
an assessment of prevention costs. Research funding was not viewed as a social cost
component either. We did, however, assess public research costs funded by the SFOPH17.
 
 Despite the fact that our review of prevention activities is not exhaustive, our results show that
expenses for primary and secondary prevention are substantial, totalling approximately 53
million Sfr. This amount is divided almost equally between primary and secondary prevention.
 
 Following the rapid development of the HIV epidemic, various prevention activities such as the
“Stop AIDS” campaign, the syringe exchange programme, and HIV screening were initiated.
Although there has been a clear improvement in the treatment of HIV patients over the last
years, particularly due to the development of new antiretroviral drugs, prevention remains an
essential tool against HIV infection.
 
 We distinguish primary from secondary prevention activities. The former is defined by the
World Health Organisation as all measures designed to reduce the incidence of disease in a
population, by reducing the risk of onset18. The latter encompasses all measures designed to
reduce the prevalence of a disease in a population, by shortening its course and duration.
 
 3.1  PRIMARY PREVENTION
 
 HIV primary prevention activities takes various forms and covers a wide range of activities
in Switzerland, as shown by Vitali et al. (1997). It includes general information to the public
such as the “Stop AIDS” campaign, programmes targeted at specific groups such as
homosexuals, intra-venous drug users, prisoners, foreign workers, schoolchildren etc. Many
actors are involved in primary prevention (the Swiss Federal Office of Public Health, cantons
and cities, Associations, etc.). An exhaustive review of all costs related to HIV primary
prevention would be therefore very complex. Instead, we focus our analysis on key
contributors of HIV primary prevention, i.e., the Swiss Federal Office of Public Health, Swiss
cantons, and the Swiss AIDS Federation. In addition, we also include condom sales and the
syringe exchange programme in our review of primary prevention activities. Although not
exhaustive, our review provides a general idea of HIV primary prevention expenses in
Switzerland.
 
                                                 
 17 The AIDS research budget of the Swiss Federal Office of Public Health amounted to approximately
    7.5 million Sfr. in 1998 (J.-J. .Thorrens , Personal communication, SFOPH)
 18 World Health Organization (1978), Glossary of health care terminology, Regional office for Europe,
   Copenhagen
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· Swiss Federal Office of Public Health (SFOPH) HIV prevention budget
 The budget of the SFOPH regarding HIV prevention  amounted to 9.3 millionSfr. in 199819.
This sum was mainly allocated to the “Stop AIDS” campaign (2.5 million Sfr.) and to the
Swiss AIDS Federation (3.3 million Sfr.) which is the parent organisation of 21 cantonal and
regional AIDS associations and another 24 organisations engaged in combating HIV and AIDS
 
· Swiss cantons and cities HIV prevention expenses
 Swiss cantons and cities do incur expenses related to HIV prevention. Data collection is
difficult due to the number of Swiss cantons and cities, and because HIV prevention activities
are often just one component of a prevention programme. Therefore, we have decided to
concentrate our efforts on data from Vaud which we consider as representative of Switzerland.
Thus, the « cantonal  budget » and the « Lausanne city budget » are extrapolated in order to
derive prevention costs for all the Swiss cantons and cities. On the one hand, this approach
may overestimate Swiss prevention costs because prevention activities in Vaud are various and
well developed, in comparison to other Swiss cantons, as shown by Vitali et al. (1997). On the
other hand, since we did not review all prevention activities, we may actually underestimate
Swiss prevention costs.
 
 The HIV prevention budget of Vaud amounted to approximately 700'000 Sfr20 in 1998 and
has been allocated to various associations active in the field of HIV prevention such as
Sid’action, Vogay, Point Fixe, etc. In addition to the “cantonal budget”, “the city of
Lausanne” has its own budget dedicated to Aids prevention which approximately amounted to
400'000 Sfr21 in 1998. Since associations in the field of HIV prevention also benefit from other
sources of income such as donations, off-budget contributions, etc., our estimate probably
tends to underestimate actual prevention expenses.
 
 In addition to HIV specific prevention activities, there are programmes such as the syringe
exchange programme. The budget for Vaud for this programme was evaluated at 493'000 Sfr.
during the year 1998. Since it also aims at preventing other health problems such as hepatitis B
and C, we consider as a baseline that only 50 % of the budget, or 246’500 Sfr, directly related
to HIV.
 
 The above elements lead to a total of 1'346'500 Sfr. for HIV prevention in Vaud. In order to
extrapolate to all the Swiss Cantons and cities, we make the following assumption. Since Vaud
represents approximately 10 % of the Swiss population, its HIV prevention expenses should
also reflect around 10 % of that of all Swiss cantons and cities. In the present study, we shall
adopt this assumption whenever we extrapolate data from Vaud to the Swiss level. On the
basis of the above assumption, we therefore estimate primary prevention costs for Swiss
cantons/cities at 13.5 million Sfr.
 
 
 
 
· Condom sales
                                                 
 19 J.J. Thorens, personal communication, SFOPH, Bern
 20  J. Resplendino, personal communication, Service de la Santé, Lausanne
 21 Y. Loehle, personal communication, Secrétariat Général - Direction de la sécurité sociale, ville de Lausanne
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 Condoms represent an effective protection against HIV infection. There has been a substantial
rise in condom sales over the last years, from 7.6 million units in 1986 to 17 million units in
199822 23. The average unit price being 0.8524 Sfr, and assuming that 50 % of the increase can
be attributed to HIV prevention, i.e., 4.7 million units, total condom sales associated with
HIV/AIDS prevention are evaluated at 4 million Sfr.
 
· Voluntary work
 Our estimate of voluntary work focuses on associations dedicated to HIV prevention.
Voluntary work represents an important component of human resources within these
associations. According to the annual report of the Swiss AIDS Federation, there were, in
1998, 530 volunteers working in the various associations, for a total of 23’600 hours.
Voluntary work is valued using the “market cost approach”. This approach places a monetary
value on voluntary work by applying the wage rate that the volunteer would have obtained for
a similar task performed on the labour market. We accept the estimate of 32 Sfr per hour
provided by Schmidt et al. (1999) to value voluntary work. Therefore, total voluntary work
amounts to approximately 0.76 million Sfr.
 
· Total Primary Prevention Expenses:
 On the basis of the different primary prevention elements presented above, we estimate total
primary prevention expenses to represent approximately 27.5 million Sfr. Alternative
hypotheses have also been examined. Attributing the entire syringe exchange program and
condom sales increase to HIV prevention would result in a total cost of 34 milli n Sfr. By
contrast, excluding the syringes exchange program and condom sales from HIV/AIDS
prevention lead to a total cost of 21 million Sfr.
 
 3.2  SECONDARY PREVENTION
 
 We shall now address the issue of secondary prevention. In this study, we consider  HIV
screening and post-exposure prophylactic treatment (PEP) as secondary prevention.
 3.2.1 HIV SCREENING
 We differentiate between “regular” HIV screening and “systematic screening”, the latter
referring to blood donations.
 
 3.2.1.1  REGULAR HIV SCREENING (WITHOUT BLOOD DONATIONS)
 Our estimate of the total HIV screening costs relies on the following elements:
 
· Total number of HIV tests performed in Switzerland in 1998 (positive and negative tests)
· Cost of an HIV test
· Cost of drawing a blood sample
· Yearly number of counselling  visits
· Cost of a counselling visit
· Administrative fees
                                                 
 22 Dubois-Arber, Jeannin A. et al. (1997), Evaluation of the AIDS prevention strategy in Switzerland, Cahier
de
    recherche et de documentation IUMSP no 120b, Lausanne
 23  Société pour le développement de l’économie suisse (1999), Sida: une maladie « à part », Numéro 29/2
 24  F. Blassel (1999), Prix du condom, l’hebdo, No 52.
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 The issue of fees versus cost arises for HIV screening components such as HIV tests and blood
sample drawing. We define as a baseline that fees are relatively close to the actual economic
cost. However, we shall also contemplate the possibility that fees and actual cost differ.
 
· Total number of HIV tests performed in Switzerland in 1998
 There are no official statistics on the number of HIV tests performed in Switzerland. However,
the number of HIV tests, not in connection with blood donations, was estimated at 300'000 in
199425. This assessment relies on a study carried out before the introduction of HAART.
Figures comparing HIV testing at the CHUV outpatient clinic before and after the introduction
of these therapies were analysed to determine if HAART had an impact on the number of
anonymous HIV tests performed. These data do not show any major changes (see Appendix
2). We thus assume that approximately 300'000 HIV tests (without blood donations) have
been performed in Switzerland in 1998.
 
· Cost of one HIV test
 The usual test performed is an ELISA test. It corresponds to position 9116.01 of the medical
analyses list of the Swiss Federal Office of Social Insurance (SFOSI) and its price is 35 Sfr.
 
· Cost of drawing a blood sample
 For each HIV test, a blood sample has to be drawn. It corresponds to position 9702.00 of the
SFOSI medical analyses list and its price is 12 Sfr. The blood sample can be used to perform
other analyses but we do not know the extent of this practice. Assuming that on the average
two analyses are performed with one blood sample, the price of blood sampling is then 6 Sfr.
 
· Yearly number of counselling visits
A counselling visit may take place before the test and/or when the test result is communicated
to the patient. Assuming that one medical visit occurs before the test, and one when the result
is communicated to the patient, would mean, on a basis of 300’000 annual HIV tests, 600’000
medical visits. Nevertheless, the following elements tend to favour a lower figure:
(i) It appears that when HIV tests are routine, as is the case with pregnant women (80'000
 cases per year), pre-test counselling is less frequent26.
 
(ii) Approximately 50 % of doctors always or often communicate HIV negative results
by telephone27.
Taking these facts into account, a figure of 500'000 yearly counselling visits seems more
accurate.
· Cost of a counselling visit.
 We rely on the Nomenclature Médicale Tarifée Vaudoise (NMTV), position 0001, to derive
the price of the counselling visit. On the basis of a counselling visit of 9 minutes, estimated by
Dubois–Arber et al. (1997), we obtain a price of  14 Sfr. for a counselling visit.
 
                                                 
 25 M. Gebhardt, Personal communication, SFOPH, Bern
 26 Dubois-Arber F., Jeannin A. et al. (1997), Evaluation of the AIDS prevention strategy in Switzerland, Cahier
    de recherche et de documentation IUMSP no 120b, Lausanne
27  idem
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· Administrative fees
An administrative fee of up to 12 Sfr. (position 9700.00 of SFOSI medical analyses list) can be
charged for each HIV test. If we again assume that two laboratory analyses are performed on
each blood sample, the administrative fee per HIV test will be 6 Sfr.
3.2.1.2  HIV SCREENING OF BLOOD DONATIONS
In Switzerland, blood donations are collected through the Swiss Red Cross and are
systematically screened for HIV. The yearly number of blood donations is around 500'00028. It
has decreased over the last years. The Swiss Red Cross itself performs the HIV tests, with
Elisa and PCR tests, which correspond to positions 9616.01 and 9116.37 of the SFOSI list of
analyses, at prices of 35 Sfr. and 275 Sfr., respectively (unit cost: 310 Sfr.)
We will, however, consider lower costs, as one can expect substantial economies of scales. In
addition, pooling, a practice that also reduces costs, is performed by the laboratories. In the
context of blood donations, we consider that screening can be performed on 30 blood samples
at a time29. Pooling means that around 16’670 HIV tests are performed instead of 500’000.
Taking into account that economies of scales further decrease the price, we assume a unit cost
ranging from 150 Sfr. to 300 Sfr.
4.1.1.1 TOTAL HIV SCREENING COST
According to the above estimates, the total cost of HIV screening is evaluated at 24.85 million
Sfr. under the main scenario detailed in Table 1.
Table 1: Total HIV screening costs: « main scenario »
Number of
HIV tests
(1)
HIV cost
per test
(2)
Blood
sampling
cost per test
(3)
Administration
fee per test
(4)
counselling
(5)
Counselling
Price
(6)
Total Cost
(1)*(2+3+4) + (5)*(6)
(1)*(2)
300'000 35 6 6 500’000 14 21'100’000
16’670
(blood
donations)
225 - - - - 3'750’000
Total 24'850’000
Two alternative scenarios have been considered as well and are detailed in Appendix 3. The
first one reflects higher costs. It assumes that there are two counselling visits per test, i.e.,
600’000 altogether, as well as a cost of 10 Sfr. per blood donation, instead of 7.5 Sfr. Under
this scenario, total HIV screening costs amount to approximately 27.5 million Sfr.
                                                 
28 J. Niklaus, Personal communication, Swiss Red Cross, Bern
29 R. Peitrequin, Personal communication, Laboratory of immunology, CHUV, Lausanne
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The second one is a lower cost scenario with 400’000 counselling visits instead of 500'000.
HIV test fee is assumed to be 28 Sfr. instead of 35 Sfr., and we consider a fee of 4.8 Sfr. rather
than 6 Sfr. for drawing blood sample. Under this scenario, total cost is evaluated at 19.7
million Sfr.
3.2.2POST EXPOSURE PROPHYLACTIC TREATMENT (PEP)
The last prevention activity that we are considering is the post exposure prophylactic
treatment. This type of treatment reduces the risk of infection after an HIV exposure and
should be administered shortly thereafter. PEP following pr fess onal exposure of health care
workers to HIV is usually distinguished from non-professional exposure (s xual contacts,
needle exchanges etc.).
In order to estimate total PEP costs, we are considering the following elements:
· Number of PEP in 1998
· Average treatment duration of a PEP
· Cost of a PEP treatment
 
· Number of PEP in 1998
 The official reported number of initiated PEP following an professional exposure to blood
has increased from 11 in 1990 to 74 in 1998 and has been stable over the last years. PEP
related to non-professional exposure is relatively recent and official data are only available
since 1997. For the year 1998, the number of reported non-professional PEP amounted to 80.
 
 The degree of underreporting for PEP treatments for both types of exposure is not well
known. It seems that it is higher for non-professional exposure. We have taken into account
the phenomenon of underreporting when assessing the total PEP cost at the Swiss level. On
the basis of SFOPH data and discussions with Dr Philippe Sudre, responsible for data
collection related to non-professional exposures, and Dr Gilbert Greub responsible for data
collection related to professional exposures, rates of underreporting of 20 % for professional
exposures and of 70 % for non-professional exposures have been assumed.
 
 Under these hypotheses, we estimate the number of PEP treatments in 1998 to be 93 for
professional exposure and 267 for non professional exposure.
 
· Average treatment duration of PEP
 Treatment is similar for both types of exposures. It usually lasts one month and combines
three antiretroviral drugs. Official recommendations regarding PEP initiation have been issued
by the SFOPH30 31.
 
 A fraction of PEP treatments are discontinued prematurely. Side effects or the confirmation
that the source patient is negative are the main reasons for treatment interruptions. In 1998, 50
% of PEP following an occupational exposure, but only 25 % following a non-professional
                                                 
 30 OFSP (1997), Mise à jour sur les expositions au VIH en milieu médical, B lletin OFSP, 7 : 5-12
 31 OFSP (1997), Recommandations prélimaires  de prophylaxie postexposition du VIH, Bulleti  OFSP, 50 : 4-8
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exposure, were interrupted32. We have estimated that premature interruption of PEP takes
place on the average after 4 days, in the case of professional exposure. This is based on
reported professional PEP data of 1998 ( G. Greub, personal communication, CHUV).
Detailed data were not available for non professional PEP. The fact that premature interruption
of PEP treatment occurs sooner for professional exposures because it is easier to test for HIV
status of the potential infection source led us to consider a duration of 8 ays before
interruption for non-professional exposure.
 
· Cost of a PEP
 The cost of a standard PEP lasting one month, i.e., antiretroviral treatment, laboratory analyses
and medical visits, has been estimated at approximately 2'300 Sfr33.
 
· Total PEP costs for Switzerland
 Components of the otal cost of PEP are depicted in Table 2. Total cost associated with PEP
is estimated at 603'000 Sfr. for the year 1998, which is less than 1 million Sfr. However, due
to the unavailability of precise data on PEP treatment, these results should be treated
cautiously. But, no matter what the scenario, the total cost would not reach 1 million Sfr.
Under the hypothesis of an underreporting rate of 30 % for professional exposure and 80 %
for non professional exposure, as well as a treatment completion rate of 50 % and 80 %
respectively, total cost would be 923'000 Sfr. By opposition, assuming there was no
underreporting regarding the official number of PEP treatments in Switzerland would result in
a total cost of 232'000 Sfr. Both alternative scenarios are detailed in Appendix 4.
                                                 
 32 P.Sudre, Non-professional Post-HIV exposure prophylaxis in Switzerland, 1997-1999, (not published)
 33 P. Sudre & B.Broers (1997), Chimioprophylaxie de l’infection VIH après exposition sexuelle ou sanguine,
   Médecine et Hygiène, 55 : 2229-2234,
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Table 2 : Cost of PEP treatments « main scenario »
Type of PEP Official
reported
PEP number
Underreporting
of  PEP (%)
Total estimated
number of PEP
Completed
PEP (%)
Interrupted
PEP (%)
Number of
completed
PEP
Number of
interrupted
PEP
PEP cost
for 1 unit
(completed)
PEP cost
for 1 unit
(interrupted)
TOTAL
cost
Professional
exposure
74 20 % 93 40 % 60 % 37 56 2’300 307 102’120
Non professional
exposure
80 70 % 267 75 % 25 % 200 67 2’300 613 500’880
603’000
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 3.3  PREVENTION COSTS: SUMMARY AND DISCUSSION
 
 The above discussion leads to an estimate of prevention costs ranging from 41 to 62 million
Sfr. A recapitulation of these costs is given in Table 3. Total prevention cost is divided  almost
equally between primary and secondary prevention.
 
 Table 3: Prevention cost components
 
 Prevention
tegy
 «Lower bound scenario» « Main scenario »  « Higher bound scenario »
 
 Primary prevention
 
 21’060’000  27’525’000  33’990’000
 Secondary Prevention
      HIV screening
      PEP treatment
 19’972’000
     19'740’0000
            232’000
 25'453'000
      24'850'000
           603’000
 28'423'000
     27'500'000
           923’000
    
 TOTAL  41’032’000  52'978’000  62'413’000
    
 
 Most probably, focusing on the main HIV prevention programmes led us to underestimate the
actual prevention cost. However, our estimate provides a basis to discuss the impact of
prevention policy.
 
 The issue of whether prevention cost savings compensate prevention expenses or not is of
interest to health policy makers. As we have seen in the first chapter, prevention is associated
with a decline in the number of new HIV infections during the last years. It is difficult to
determine the precise contribution of HIV prevention to this decline. Assuming that in
comparison with 1991 (2’144 new infections), 50 % of the decline in the number of new
infections in 1998 (657 new infections in 1998) were attributable to prevention, means that
prevention avoided 744 yearly cases at a cost of approximately 52.98 million Sfr., i e., 71’210
Sfr per avoided HIV infection case. W  adopted 1991 as our baseline year because it is since
that year that the yearly number of new HIV infections began to decline. Our estimate may
actually overestimate the actual cost per avoided HIV cases, since it ignores the impact of
prevention until 1991. In addition, we also consider that over the last years prevention
expenses have been relatively stable. Now, if we were to consider 140 million Sfrfor total
prevention costs at Swiss level, as estimate earlier by Vitali et al. (1997), the cost per avoided
case would then amount to 188’170 Sfr. These results should then be compared to the costs
attributable to one case of a HIV infection. These costs will be analysed in the following
chapters.
 
 
 
  29
 
 4  DIRECT COSTS
 
 In this chapter, we evaluate the direct costs of HIV infection. We differentiate between
outpatient and inpatient care. The former relates to drug treatments (including antiretroviral
treatments), ambulatory medical visits, psychotherapy, and home care, whereas the latter is
associated with hospital and institutional psycho-social care.
 
 Due to HIV infection characteristics, assessing HIV direct costs is complex. Persons living
with the HIV infection may suffer from very different diseases and the causality between the
latter and the HIV infection can sometimes be difficult to determine.
 
 This issue can be approached from two different points of view:
 
· The first one consists in determining a percentage of associated diseases attributable
to HIV infection. For instance, 80 % of all zona cases among HIV infected individuals
can be attributed to HIV infection.
 
· The second one is a case control approach. HIV positive and negative individuals are
matched by age, risk group (homosexual, intra-venous drug users, heterosexual), social
class, etc., and their health costs are then compared.
While the second approach is in principle preferable, it is very demanding in practice because
of difficulties associated with the matching procedures. Our data did not allow us to pursue
this approach and as a result the first approach , despite a certain arbitrariness in determining
the percentage attributable to HIV infection, was adopted.
4.1  OUTPATIENT CARE
We consider two outpatient care categories, i.e., HIV related drug treatments and HIV
related medical and paramedical care (ambulatory medical visits, psychotherapy, and home
care).
4.1.1  DRUG TREATMENTS RELATED TO HIV
Since HAART introduction, drugs have become the key element in HIV care. It should be
noted that drug consumption is not limited to antiretroviral drugs. Other medications are also
taken by HIV infected individuals. The following drug categories are analysed:
. Antiretroviral drugs
These drugs aim at preventing HIV replication. They are only used against HIV infection. Our
main data source was Swiss Pharma data and SHCS data.
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. Co-morbidity drugs
These drugs are used either to prevent or to treat HIV co-morbidity. They are aimed at
preventing and/or treating pneumocystis carinii pneumonia, toxoplasmosis, mycobacterial,
fungal, viral infections and neoplasms. The SHCS data were our main source of information.
. Co-medication
We also incorporated drugs that are less specifically related to HIV infection, such as
neuroleptics, antidepressants, vitamins, etc. For these drugs, consumption data of HIV infected
individuals are based on a recent study34 a sessing the impact of such drugs on HAART
effectiveness.
· ANTIRETROVIRAL DRUGS
 
 Figures related to antiretroviral drug sales in Switzerland are scarce. Pharma Information35
provides a global estimate of 91.4 million Sfr. for 1998. To gain insight of the different
antiretroviral drug cost components, detailed costs were calculated for the SHCS individuals
in 1998.
 
 The following elements were determined in order to derive the cost for each drug:
 
· Treatment duration 
 The treatment duration was derived from the SHCS data base.
 
· Standard daily dose
 Our figures are based on the standard dosage of each antiretroviral drug as administered to
HIV patients.
 
· Cost per unit
 We selected public prices to calculate the cost per unit of each drug.
 
 Based on these elements, we estimated the total antiretroviral drug costs for the SHCS
individuals at 58.3 million Sfr. in 1998. The details are found in Table 4.
 
 
 
 
 
 
 
 
 
 
                                                 
34 Marzolini C. (2000), Therapeutic drug monitoring for protease inhibitors and effavirenz, CHUV, Lausanne
    (Unpublished data)
 35 Pharma Information (Association des Maisons de Recherche Pharmaceutique Suisses), Bâle
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 The five most frequently prescribed drugs are Combivir®, Zerit®, Viracept®, Crixivan® and
Epivir®, which represent approximately 80 % of the total cost.
 
 Table: 4 Antiretroviral cost of the SHCS in 1998
 
 
 
 Based on the SHCS data, we found that in 1998 approximately 70 % of the patients were
under HAART (3 or more antiretrovirals), 10 % were under a bi-therapy (2 antiretrovirals),
while around 20 % were not treated. Of the 20 %, 10 % were not treated at all during 1998
and the remaining 10 % corresponds to a time equivalent of patients who only received
treatment during part of the year.
 
 We estimate at 15’000 Sfr. the average yearly cost for an individual under antiretroviral
treatment in the SHCS. This amount accounts for the fact that 10 % of SHCS individuals are
under bi-therapy (less expensive than HAART) and that others had treatment interruptions.
 
 Estimating the number of individuals under antiretroviral treatment in Switzerland is of interest
to public health decision makers. Under the hypothesis that average treatment cost is similar
for individuals treated within or outside the SHCS, the number of HIV individuals in
Switzerland under antiretroviral treatment would reach a total of approximately 6’100 in 1998
(91.4 million Sfr./15’000 Sfr.). Out of the estimated 6’100 treated patients, 4’050 are in the
SHCS. i.e., 65 % of all HIV patients treated in Switzerland would belong to the SHCS.
These results indicate that SHCS patients account for the majority of treated patients in
Switzerland. Furthermore, since the estimated number of persons living with HIV infection in
Switzerland is between 11’000 and 21’000, the figure of 6’100 treated patients means that a
large fraction of HIV positive individuals are not treated. Our data and the framework of the
study do not allow us to investigate further this interesting public health issue. However, the
discrepancy between the number of individuals living with HIV infection in Switzerland and
our estimate of treated patients might also be explained by the lack of data on the actual
number of individuals living with HIV infection in Switzerland.
 
 
 
 
Trade Mark Daily dose Price per unit Sfr. Daily Price Sfr. Total consumption (days) Total Cost Sfr. 
COMBIVIR®            2 tab 13.52 27.04 446 571                                12 075 283      
ZERIT®               2 cps 7.90 15.80 705 323                                11 141 584      
VIRACEPT ®            10 tab 2.41 24.14 408 557                                9 864 382        
CRIXIVAN®              6 cps 3.43 20.58 347 094                                7 143 195        
EPIVIR® 2 tab 7.89 15.79 399 914                                6 313 976        
NORVIR®                8 cps 1.81 14.45 266 898                                3 855 405        
VIDEX®                4 tab 4.22 16.88 182 339                                3 077 882        
INVIRASE®              4 cps 2.41 9.66 213 961                                2 066 388        
ZIAGEN® 2 tab 11.70 23.40 38 449                                  899 771            
RETROVIR®              2 cps 8.46 16.93 39 991                                  676 848            
VIRAMUNE®              2 tab 7.63 15.26 31 691                                  483 710            
AGENERASE® 16 tab 2.11 33.68 7 118                                    239 734            
HIVID®                 4 tab 3.98 15.91 10 145                                  161 366            
STOCRIN®               3 cps 5.62 16.85 9 462                                    159 435            
LITALIR®               3 tab 1.41 4.23 23 983                                  101 556            
FORTOVASE®             18 cps 1.48 26.60 1 637                                    43 546              
TOTAL 58 304 060      
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· CO-MORBIDITY DRUGS
 
 The cost of these drugs has been estimated for the SHCS. Estimates are significantly lower
than for antiretroviral drugs and vary between 1.7 million Sfr. for anti-fungal drugs and 0.630
million Sfr. for anti-mycobacterial drugs. The total amount for these drugs is estimated at 5.8
million Sfr. which corresponds to approximately 10 % of SHCS antiretroviral drug costs. The
detailed data for these drugs are displayed in Appendix 5.
 
 Extrapolation of these costs for Switzerland is based on a ratio representing the share of SHCS
antiretroviral costs in the total cost of antiretroviral drugs at Swiss level. This ratio was
estimated to be 65 % (58.3/91.4 million) which gives a total co-morbidity drug cost in
Switzerland of  9.1 million Sfr.
 
 
·  CO-MEDICATION DRUGS
A good picture of such drugs is provided by the “therapeutic drug monitoring for protease
inhibitors and effavirenz” study”. Approximately 750 HIV patients are enrolled in this study
and are regularly asked to indicate which medication (any medication) they are taking at the
time of the interview. The most consumed co-medication by HIV patients are antidepressants
and neuroleptics. Details related to co-medication drugs are found in Appendix 6. On the basis
of these data, we estimate a yearly consumption per capita of 730 Sfr.
These drugs are not specifically related to HIV infection. In addition, some are even “over the
counter” drugs. Remaining conservative, we assume  that 50 % of these drugs are related to
HIV infection, which represents a total cost of 2.92 million Sfr. at the Swiss level, considering
that there are 8’000 medically followed HIV patients36. The difficulty to determine the extent
to which co-medication drugs are related to HIV and the number of medically followed
persons living with HIV infection led us to consider two alternatives. On one hand, assuming
that these drugs are not related to HIV infection means a total co-medication drug costs of
zero.  On the other hand, co-medication drug costs would reach 7.30 million Sfr. if we
consider 10’000 HIV patients in Switzerland instead of 8’000 and that these drugs are entirely
related to HIV infection.
                                                 
36 See sub-section 4.1.2.1 for details on the assessment of the number of HIV patients in Switzerland
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4.1.1 MEDICAL AND PARA-MEDICAL CARE
In this section, we examine medical and para-medical care associated with HIV infection. The
following sub-categories are differentiated:
(i) Ambulatory medical visits
We rely on two different sources of information to determine ambulatory medical care
costs, namely the CHUV HIV outpatient clinic and private practitioners. Four private
practitioners collaborated with our study and accepted to provide us with data on HIV
positive patients (50 patients altogether).
(ii) Psychotherapy
Since HIV infection can affect mental health, psychotherapy is also included in our
study. Expert opinion was our main source of information, since data related to HIV
patients and psychotherapy are scarce.
(iii) Home care
For some patients, home care is an alternative to hospitalisation  or to inpatient care in
a specialised institution. Our cost assessment is based on home care federation data and
on an unpublished study by M. Alberti37 on HIV and home care in Vaud.
4.1.2.1 AMBULATORY MEDICAL VISITS
The measurement of ambulatory medical visit costs for the year 1998 combines the following
elements:
. Yearly medical visit costs per HIV patient
. Number of HIV patients under medical follow-up in Switzerland
Drug costs are not included in ambulatory medical visit cost assessment as they are already
accounted for in sub-section 4.1.1.
I) YEARLY MEDICAL VISIT COST PER HIV PATIENT
The CHUV HIV outpatient clinic and four private medical practitioners helped us determine
the yearly medical visit cost per HIV patient.
· CHUV HIV Outpatient clinic
 The CHUV financial department provided us with cost data for the 416 HIV infected  patients
followed by the HIV outpatient clinic in 199838. Costs attributable to HIV infection were
determined with the collaboration of Dr Greub39. A systematic review of each patient in order
to determine costs attributable to HIV infection was not feasible, due to the number of
                                                 
37 M. Alberti (1999), L’infection VIH en 1998, Lausanne (unpublished data)
 38 Data were anonymised
 39 CHUV HIV outpatient clinic, Lausanne
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patients. Instead, we concentrated on the different types of medical acts and determined which
proportion was attributable to HIV infection.
· Private Medical Practitioners
 Four private medical practitioners treating HIV patients collaborated with our study40. They
provided us with data about their patients (50 altogether), including patients’ bills41. The same
approach as for the CHUV HIV outpatients was adopted. In addition, the smaller number of
patients allowed us to perform a systematic review, using a questionnaire elaborated with the
help of the private practitioners (see Appendix 7).
 
· Average yearly cost
 Based on the above elements, we estimate yearly medical visit costs per HIV patient at  3’000
Sfr. This amount reflects the average yearly cost attributable to HIV infection.
 
 
 II)   NUMBER OF HIV PATIENTS UNDER MEDICAL FOLLOW UP IN
       SWITZERLAND
 
 In sub-section 4.1.1, we established that the number of HIV individuals under antiretroviral
treatment was approximately 6’100 in Switzerland in 1998. However, these patients do not
represent the total number of HIV individuals under medical follow-up. A fraction of HIV
patients seen by medical doctors are not under antiretroviral treatment. A panel of experts42
estimated that these patients could represent between 20 % and 30 % of HIV patients followed
by either specialists for infectious diseases or general practitioners. Therefore, 8’000 medically
followed HIV patients seems a more accurate figure. This figure remains below the estimated
11’000 to 21’000 individuals living with HIV infection in Switzerland.
 
 III)  TOTAL AMBULATORY MEDICAL VISIT COSTS
 
 Combining the above elements result in a total ambulatory visit cost of 24 milli n Sfr. in
Switzerland for the year 1998. Alternatively, we also considered the impact on ambulatory
medical visit costs of a higher and a lower number of medically followed HIV patients in
Switzerland. If we assume that there are 10’000 HIV patients, this would mean a total
ambulatory medical visit cost of 30 million Sfr. On the other hand, hypothesising that only 10
% of all HIV treated patients are not under antiretroviral treatments, i.e. 6’800 HIV patients
under medical follow-up,  would result in a total cost of 20.4 million Sfr.
 
 
 
                                                 
 40 Dr C. Jaccard, Lausanne, Dr C. Junet, Genève, Drs J. Wintsch, Genève, Dr. R. Jaccard, Zurich
 41 Bills have been anonymised in order to preserve medical secrecy
 42 Dr C. Jaccard, Lausanne, Dr R. Jaccard, Zurich, Dr M. Gebhardt SFOPH, Bern, Dr A. Telenti, CHUV,
  Lausanne
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 4.1.2.2 PSYCHOTHERAPY
 
 Psychotherapy treats a wide range of mental problems that are common to persons living with
HIV infection such as anxiety, depression and social dysfunction43.
 
 The psychotherapy cost assessment relies on the three following elements:
 
· Proportion of HIV infected patients undergoing a psychotherapy
· Session frequency
· Cost of a psychotherapy session
 
·  Proportion of HIV infected patients undergoing a psychotherapy
 Our estimate relies on the proportion of CHUV HIV outpatients undergoing  psychotherapy.
This proportion is estimated at 10 % (P. Cochand, personal communication, CHUV). Since
there are 8’000 medically followed patients in Switzerland (see sub-section 4.1.2.1), one can
expect approximately 800HIV patients under psychotherapy. Some patients might have been
undergoing a psychotherapy before contracting HIV infection. However, as one can assume
that HIV infection is also a central element of their mental health problem, we consider all
psychotherapy as related to the HIV infection.
 
· Session frequency
 Our estimate of session frequency is also based on the frequency patterns of the CHUV HIV
outpatient clinic. Among patients under psychotherapy, approximately 60 % are s en three
times a year and 40 % once per week (P. Cochand, personal communication, CHUV).
 
· Cost of a psychotherapy session
 The average cost of a session varies between 115 Sfr. (Nomenclature Médicale Tarifée:
Position 13) and 150 Sfr. (Tarifs Vaudois de remboursement des assurances complémentaires:
Position 7001). We consider an average cost of 130 Sfr.
 
 Total psychotherapy costs for Switzerland in 1998 are evaluated at 2.35million Sfr. This
amount would reach 2.94million for HIV patients,  if we consider 1’000 patients rather than
800. This increase would be based on a total number of 10’000 medically followed HIV
patients. On the other hand, if we assume that they were 6’800 HIV patients, this would result
in a total cost of 2 million Sfr. for psychotherapy.
 
 
 
 
 
 
 
 
 
 
 
                                                 
 43 Catalan J. Meadows J. and Douzenis A. (2000), The changing patterns of mental health problems in HIV
   infection, AIDS Care, 12 : 333-341
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 4.1.2.3  HOME CARE
 
 Home care includes various types of care such as nursing care, ergotherapy, social workers
visits, and housework help. Data on HIV and home care are scarce in Switzerland.
 
 Since HIV patients are relatively young, we assume that home care for HIV infected
individuals is entirely attributable to HIV infection, 70 % of home care beneficiaries being
above 64 (OFAS, 2000).
 
 We derive total home care costs on the basis of:
 
· Total number of home care hours for persons living with HIV infection in Vaud and
extrapolation for Switzerland
· Average cost per hour
 
 
· Total number of home care hours for persons living with HIV infection in Vaud and
extrapolation for Switzerland
 A study estimated the number of HIV infected individuals benefiting from ursi care in
Vaud to be around 44 in August 199944. Of these, 34 had regular care, i.e., one visit every 2
weeks, while 10 had sporadic visits, i.e., one visit per month on average. This corresponds to
approximately 78 visits on a monthly basis or 936 on a yearly basis.
 
 As average nursing care visit  lasts 30 minutes45, the corresponding yearly number of home
care hours adds  up to 468 hours for Vaud in 1998.
 
 No similar studies exist for the remaining types of home care. We therefore  estimated these
hours calculating the ratio between nursing care visits and the other types of care, based on
official home care statistics of Vaud. The result, a total of 2'476 hours for 1998, is detailed in
Table 5.
 
 Table 5: Home care monthly visits in Vaud
 
 Type of Visits  Number of monthly
visits
 Ratio Nurses visits wrt
other visits
 Number of
monthly visits
(HIV patients)
 Average
length of
visit
 Total number
of yearly hours
(HIV patients)
 Nurses
 
 31’609  1  78  30
minutes
 468
 Social workers
 
 2’664  0.08  6  40
minutes
 48
 Ergotherapist
 
 2’079  0.07  5  50
minutes
 50
 House work
help
 
 77’456  2.45  191  50
minutes
 1’910
 TOTAL
 
     2’476
                                                 
 44 M.Alberti (1999), l’infection VIH en 1998, Lausanne  (unpublished data)
 45 Centres Médico-Sociaux (1997), Les prise en charge médico-sociales intensives à domicile, OMSV,
Lausanne
  37
 
 We again apply the 10 % ratio to extrapolate from Vaud to Switzerland. Under this
hypothesis, the number of home care hours in Switzerland would be 24’760 for the year 1998.
· Average cost per hour
 Swiss home care statistics published by the Swiss Federal Office of Social Insurance estimate
the Swiss average cost per hour at 72 Sfr46.
 
· Total costs of home care for persons living with HIV infection in 1998
We evaluate the total cost of home care for HIV infected individuals at 1.8 million Sfr.
(24'760 hours * 72 Sfr.).
We also examined two different scenarios detailed in Appendix 8. The first one assumes a
more extensive use of home care, whereas the second one is more conservative. Their
respective costs are  4 million Sfr and 1 million Sfr.
4.2   INPATIENT CARE
In this section, inpatient care costs are measured. We differentiate between hospital care and
institutional psycho-social care.
4.2.1HOSPITAL CARE
In order to assess hospital care costs in Switzerland for the year 1998, we consider the
following elements:
· Number of hospitalisations of HIV infected individuals in Switzerland
· Proportion of hospitalisations attributable to HIV/AIDS
· Cost per « All Patient Diagnosis Related Group » (APDRG) for HIV/AIDS related
diseases
 
· Number of hospitalisations of HIV infected individuals
 HIV infected individuals are hospitalised with a large spectrum of diagnoses and
hospitalisations might be exclusively, partially or totally unrelated to HIV/AIDS.
 
 We collected data about all hospitalisations of HIV individuals in Switzerland during 1998,
whatever the cause of hospitalisation. The Swiss Federal Office of Statistics (SFOS) provided
us with Swiss hospitalisation data of HIV positive patients. Diagnosis classification is currently
based on 10th version of the International Classification of Diseases (ICD-10). Swiss hospitals
are now required to use ICD-10 for their hospitalisation statistics. Prim ry and secondary
diagnoses are used to classify hospitalised patients. The primary diagnosis is the main reason
for hospitalisation, whereas secondary diagnoses relates to co-morbidity factors.
 
 These statistics have been recently implemented in Switzerland. It is estimated that for the year
1998, the SFOS collected data for 60 % of all Swiss hospitalisations (Gaspoz, personal
communication, SFOS). The SFOS registered 1’536 hospitalisations of HIV patients in
                                                 
 46 Office Fédéral des Assurances Sociales  (2000), Statistique de l’aide et des soins à domicile 1998, Berne
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Switzerland for the year 1998. Extrapolating this figure to all hospitalisations in Switzerland,
we estimate that the number of hospitalisations of HIV patients in Switzerland amounted to
2’560 in 1998.
 
 We differentiate between HIV patients hospitalised with an HIV primary diagnosis from
those hospitalised with another primary diagnosis, meaning HIV is a secondary diagnosis.
The former represent 845 cases or 33 % of all hospitalisations of HIV patients, and the latter
1’715 cases or67 % of all hospitalisations.
 
 Table 6 displays the 845 HIV primary diagnoses. The most frequent diagnoses are unspecified
HIV disease (290 cases or 34 %), HIV disease resulting in multiple infections (85 cases or 10
%), HIV disease resulting in encephalopathy (57 cases or 7 %), and HIV dise se resulting in
pneunocystis carinii pneumonia (53 cases or 6 %).
 
 Table 6: HIV primary diagnoses
 
 ICD-10  Diagnosis  Number of cases
 
 B 24  Unspecified HIV disease  290
 B 207  HIV disease resulting in multiple infections  85
 B 220  HIV disease resulting in encephalopathy  57
 B 206  HIV disease resulting in Pneumocystis carin i pneumonia  53
 B 208  HIV disease resulting in other infectious and parasitic disease  48
 B 238  HIV diseases resulting in other specified conditions  42
 B 200  HIV disease resulting in mycobacterial infection  40
 B 209  HIV infection resulting in unspecified infectious or parasitic disease  38
 B 201  HIV disease resulting in other bacterial infections  37
 B 212  HIV disease resulting in other types of non-hodgkin’s lymphoma  27
 B 204  HIV disease resulting in candidiasis  25
 B 227  HIV disease resulting in multiple diseases  18
 B 202  HIV disease resulting in cytomegaloviral  disease  15
 B 230  Acute HIV infection syndrome  13
 B 222  HIV disease resulting in wasting syndrome  10
 B 203  HIV disease resulting in other viral infections  8
 B 231  HIV disease resulting in (persistent) generalised lymphadenopathy  7
 B 232  HIV disease resulting in haematological and immunological abnormalities 7
 B 210  HIV disease resulting in Kaposi’s sarcoma  5
 B 221  HIV disease resulting in lymphoid interstitial pneumonia  5
 B 205  HIV disease resulting in other mycoses  3
 B 211  HIV disease resulting in Burkitt’s lymphoma  3
 B 213  HIV disease resulting in other malignant neoplasms of lymphoid, haematopoietic
and related issue
 3
 TOTAL   845
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 The most frequent primary diagnoses of hospitalisations with HIV as secondary diagnosis are
depicted in Table 7 (see Appendix 9 for a review of all diagnoses). There is a large variety of
diagnoses covering 492 ICD-10 codes. This variety is illustrated by the fact that the 10 most
frequent diagnoses account for less than 30 % of all diagnoses.
 
 Table 7: Most frequent primary diagnoses with HIV as secondary diagnosis
 
 ICD-10  Diagnosis  Number of cases
 
 F 192  Mental and behavioural disorders due to multiple drug use and use of other
psychoactive substances
 77
 J 159  Bacterial pneumonia  35
 F 112  Mental and behavioural disorders due to use of cannabinoids  32
 A 630  Anogenital (venereal) warts  30
 J 189  Pneumonia  28
 R 509  Fever  28
 J 013  Acute sphenoidal sinusitis  25
 K 85  Acute pancreatitis  25
 L 024  Cutaneous abscess, furuncle and carbuncle of buttock  22
 O 049  Medical abortion  22
 N 871  Moderate  cervical dysplasia  17
 Z 515  Palliative care  17
   
 
 
· Proportion of hospitalisations attributable to HIV/AIDS
 In order to estimate the proportion of hospitalisations attributable to HIV infection, we
adopted the following five categories reflecting five different causality levels between  HIV
infection and hospitalisation:
 
 . Exclusively related  (100 %)
 . Strongly related  (80 %)
 . Moderately related (50 %)
 . Weakly related  (20 %)
 . Not related (0%)
 
 These percentages will allow us to determine hospitalisation costs attributable to HIV
infection. Each primary diagnosis of hospitalisation with HIV as secondary diagnosis was
reviewed and classified in one of the five categories. This work was done by medical doctors
treating HIV patients47. The results are detailed in Appendix 10.
 
· Cost per APDRG for HIV/AIDS related diseases
 We rely on APDRGs to estimate hospitalisation costs. APDRGs are a hospitalisation
classification scheme originally developed as a means of relating the type of patients a hospital
treats to the cost it incurs. Homogenous categories from both a clinical and economic
                                                 
 47 Dr. G. Greub, CHUV, Dr C. Jaccard, Internal Medicine, Lausanne
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perspective have been established. The 12th version APDRG is composed of 25 major
diagnosis categories (including one HIV category) and 641 hospitalisation groups48.
 
 
 Hospitalisations are classified in APDRGs according to the following variables:
 
 . Diagnoses (primary/secondary),
 . Intervention (surgical procedures)
 . Age and sex
 
 Cost per APDRG should become the official reimbursement mode for Swiss hospitals within a
few years. We have adopted this system to calculate hospitalisation costs because it better
reflects actual hospitalisation cost than the current system based on a average reimbursement
per day paid to hospitals whatever the diagnosis.
 
 In order to implement this new system, the CHUV, the Hôpital Cantonal de Genève , the
Zürich Universitätsspital, the Hôpital de Morges, and the Group of regional hospitals from
Canton of Ticino have estimated cost weights for each APDRG. For our calculation, we used
the APDRG cost-weights 2nd version49. The average unit cost (cost-weight of value 1) has been
estimated at 10'000 Sfr50. Diagnoses of HIV positive patients hospitalised in Switzerland
during 1998 were matched with  their corresponding APDRG and cost-weight. This procedure
was realised by the SFOS.
 
· Total hospital care costs for Switzerland
 Our assessment of hospital care costs related to HIV/AIDS in Switzerland for the year 1998
combines the previous elements. An example of the calculation mode per hospitalisation is
provided in Table 8. The primary diagnosis of hospitalised HIV patient is displayed in column
two, and the average proportion of hospitalisations attributable to HIV infection in the third
column. The corresponding APDRG, and its cost-weight constitute the fourth and fifth column
respectively.
 
 Table 8: Cost per APDRG attributable to HIV infection
 
 ICD-10  Diagnosis  Average
proportion
attributable to
HIV
 
 (1)
 APDRG denomination Cost-
Weight51
 
 (2)
 Total cost
 
 
 (1000)*(1)*(2)
 B 24  Unspecified HIV disease  100 %  HIV with major related
diagnosis without
multiple major or
significant diagnosis
without TB
 1.26  12’600
 B 207  HIV disease resulting in
multiple infections
 100 %  HIV with multiple
major related infections
 6.34  63’400
                                                 
 48 Major groups are detailed in Appendix 11
 49 Institut d’Economie et de la Santé (2000), Manuel APDRG Suisse: version 2.0, Lausanne
 50 H. Guillain, Personal communication, Institut d’Economie et de la Santé, Lausanne
 51 For the same diagnosis, the cost-weight might vary according to the average hospital length of stay
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without TB
 F 192  Mental and behavioural
disorders due to multiple
drug use and use of
other psychoactive
substances
 20 %  Cocaine or other drug
abuse or dependence
with complications
 0.68   1’360
 J 159  Bacterial pneumonia  80 %  Respiratory disorder
except infections,
bronchitis, asthma with
major complications.
 1.8  14’400
      
 We obtain hospitalisation costs by multiplying together the average proportion attributable to
HIV infection, its respective cost-weight and the average cost-weight (10'000 Sfr)
 
 We evaluate total hospital care costs related to HIV infection in Switzerland to be 32.3 million
Sfr. for the year 1998. Detailed data are presented in Appendix 12.The average cost per
hospitalisation for patients with an HIV primary diagnosis is 24’000 Sfr. This amount is lower
for HIV patients hospitalised with a primary diagnosis other than HIV. The average cost per
hospitalisation attributable to HIV is 7’100 Sfr., whereas the overall cost per hospitalisation is
estimated at 14’800 Sfr.
 
 Since defining the extent to which a diagnosis is related to HIV is somewhat arbitrary, we also
consider the two extremes in which only AIDS defining conditions are included and another in
which any cause of hospitalisation of HIV patients is assumed to be entirely related to HIV
infection. Total hospitalisation would amount to 20.15 million Sfr  and to 45.59 million Sfr.
respectively.
 
 
 4.2.2 SPECIALISED INSTITUTIONAL PSYCHO-SOCIAL CARE
 
 Finally, we assess costs resulting from specialised institutional psycho-social care for HIV
patients. “Le Soleil Levant”, an example of such an institution in Lausanne, provides psycho-
social support, palliative care, adaptation to therapies and follow up for hospitalisation.  We
consider the type of care as inpatient care globally, since ambulatory care represents only a
small portion of the services provided by the “Soleil Levant”.
 
 We derive our assessment of specialised institutional psycho-social care at the Swiss level from
the “Soleil Levant” institution. Since such institutions are specialised in psycho-social care for
persons living with HIV infection, we consider the care they provide as entirely attributable to
HIV infection.  Psycho social support activities at the Soleil Levant corresponded to 2’771
inpatient days and 381 outpatient days in 1998. Costs associated with such activities are
estimated at 430’000 Sfr52. Extrapolating to the Swiss level means that this type of care
represented approximately 4.3 million Sfr. in 1998. Our extrapolation, based on the
assumption that Vaud costs represent 10 % of Swiss costs, might be questionable because
institutions like the “Soleil levant” do not exist in every Swiss canton. Therefore, institutional
psycho-social care costs might be overestimated. This may be balanced by the fact that there
are other parallel psycho-social structures which we have not considered. Assuming that our
cost assessment overestimates total institutional psycho-social care by approximately 20 %,
                                                 
 52 Monique Prahin, personal communication, Le Soleil Levant, Lausanne
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means that total cost would be 3.44 million Sfr. Alternatively, total institutional psycho-social
care would reach 5.16 million Sfr. if we actually underestimate costs by  the same proportion.
 
 
 
 
 4.3  DIRECT COSTS: SUMMARY AND DISCUSSION
 
 Total direct costs attributable to HIV/AIDS in Switzerland amounted to approximately 168
million Sfr. for the year 1998. Alternative assumptions, detailed in the previous sub-sections,
were also examined. More conservative hypotheses would result in a total cosof 143 million
Sfr, whereas it would reach 201 million Sfr. under less conservative assumptions, as
illustrated in Table 9.
 
 One central result presented in Table 9 is the importance of antiretroviral costs, estimated at
91.4 million Sfr., emphasized by the fact that they account for more than 50 % of total direct
costs. In addition, their share remain significant under both alternative scenarios. One of the
consequence of the magnitude of antiretroviral drug costs is that outpatient care costs exceed
inpatient care costs. The different outpatient care categories add up to 132 million Sfr.
whereas inpatient care reaches 36 million Sfr. Medical visit costs, the second outpatient
main category, are significantly lower than antiretroviral costs and amount  to 24 milli n Sfr.
Finally, Hospital care costs, he major inpatient cost component, are  estimated at 32 illion
Sfr.
 
 This cost pattern is not unique to Switzerland. Bozette et al. (2000), in their study assessing
HIV medical care costs in the United States, estimate that drug costs account for about 50 %
of total direct medical costs. Prior to the introduction of HAART therapy, costs patterns were
characterised by the importance of hospital care costs.  Postma et al. (1995) estimated that
hospital care costs, in 1993, represented up to 85 % of total direct costs in the Netherlands.
The transfer from inpatient to outpatient care cost is confirmed by the observational cohort
study of Gebo et al. (1999) who found that, between 1995 and 1997, hospital inpatient
payments decreased significantly for patients under HAART whereas pharmacy payments
increased significantly.
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              Table 9: Direct cost components (Sfr.)
 
 Direct cost components  Lower Bound Scenario  Percentage  Main scenario  Percentage  Higher Bound Scenario Percentage
   OUTPATIENT CARE       
 HIV related drug treatments       
    Antiretroviral drugs   86’830’000  61 %  91’400’00053  54 %           95’970’000      48 %
    Co-morbidity drugs     8’683’000   6 %   9'140’00054    6 %             9’597’000        5 %
    Co-medication           -   -   2’292’000    2 %            7’300’000        4 %
 Medical and Para-Medial Care       
    Ambulatory medical visits   20’400’000  14 %  24’000’000  14 %           30’000’000      15 %
    Psychotherapy     1’998’000   2 %   2’350’000    1 %             2’938’000        1 %
    Home care     1’080’000   1 %   1’780’000    1 %             4’080’000        2 %
   TOTAL OUTPATIENT CARE  118’991’000  84 %      131’590’000  78 %         149’885’000      75 %
       
   INPATIENT CARE       
 Hospital care   20’150’000  14%  32'290’000  19 %           45’590’000      23 %
 Institutional psycho-social care     3’440’000   2 %   4’300’000    3 %             5’160’000        3 %
   TOTAL INPATIENT CARE   23’590’000  16 %        36’590’000  22 %           50’750’000      26 %
       
       
                                                 
 53 This figure represents a global estimate communicated by Pharma Information (see sub-section 4.1.1). We consider a variation of plus or minus 5 % of the standard
amount
 54 For both alternative scenarios, we still assume that co-morbidity drugs represent 10 % of antiretroviral drugs
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 TOTAL COSTS  142’581’000      100 %      168’180’000      100 %         200’635’000     100 %
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 One question arising is whether the increase in antiretroviral drug costs over the last years has
been outweighed by a decrease in hospital care costs. Bozette et al. (2000) provide a positive
answer to that question. They conclude that on average, annual heath care expenditures per
HIV patient in the United States declined from 20’300 USD in 1996  (1 USD = 1.24 Sfr.,
1996) to 18’300 USD in 1998 (1 USD = 1.45 Sfr., 1998). However, this difference is not very
large and one should be cautious when generalizing this result to other countries.
 
 In Switzerland, we estimate annual direct costs per HIV patient at 21’000 Sfr. (171’229’000
Sfr./8’000 patients) for the year 1998. Güntert et al. (1997) evaluated at 70’500 Sfr. the
lifetime cost of  treating an HIV patient prior to the introduction of effective antiretroviral
treatments. As they assumed a life expectancy of 12 years for HIV infected patients, this means
an average annual cost per patient of 5’875 Sfr. On the basis of this figure, one might consider
that HAART costs are not outweighed by a corresponding decrease in hospitalisation costs.
However, one should bear in mind that different methodologies were used, and that a long time
period separates both studies. Güntert et al. cost assessment reflect the lifetime cost of patients
deceased between 1991 and 1993. Therefore, these patients did not actually benefit from
antiretroviral drugs. Since then, HIV disease prognosis has so drastically  changed, that a
comparison relying only on costs is not very meaningful, and one should also take into
consideration life expectancy gains resulting from HAART introduction.
 
 As mentioned above, the annual cost per HIV infected patient is substantial and amounted to
21’000 Sfr. in Switzerland for the year 1998. However, total HIV direct costs at Swiss level
are inferior to other public health concerns such as tobacco related diseases and stress. Direct
costs associated with tobacco related diseases were evaluated at 1’211 million Sfr. in 1995
(Frei, 1998). The amount for stress direct costs is even more important and was estimated at
1’761 million Sfr. in 1998 by Ramaciotti and Perriard (2000). The relatively low HIV
prevalence explains this phenomenon.
 
 All in all, HIV infection direct costs accounted for approximately 0.5 % of total Swiss health
care costs (37 billion Sfr) in 1998. This result was relatively similar for the United States where
HIV total direct costs were estimated at 6.8 billion (Bozette et al., 2000), representing around
0.6 % of total US health care expenditures in 1996. One should not however conclude that
HIV direct costs are not important. The annual cost per patient remains high (21’000 Sfr.) and
prevention cannot be neglected within the frame of a public health policy.
 
 Finally, one limitation of our cost assessment stems from the fact that it does not include direct
non health care costs. The latter are non-health care resources consumed as a part of an health
care intervention (Gold et al. 1996). They include, for example, transportation cost to and from
the outpatient clinic and costs resulting from a specific dietary prescription.
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 5  INDIRECT COSTS 
 
 In this chapter, indirect costs attributable to HIV infection in Switzerland are measured.
Assessing indirect costs requires the evaluation of the following elements:
 
· Morbidity costs which relate to lost or impaired ability to work
· Mortality costs  which are associated with premature death
Morbidity and mortality costs represent the value of goods and services that HIV positive
individuals would have produced had they not contracted the disease.
In what follows, we describe our methodological approach. Then, we move on to the
presentation of the results, and finally summarize and discuss our major findings.
5.1  METHODOLOGY
We adopt the uman capital approach to assess indirect costs. Human capital refers to the
productive capacities of human beings as income producing agents in the economy55. Human
capital is the stock of skills and productive knowledge embodied in  people. This method is a
standard one and has been used for many years. It measures productivity losses to society,
using  market wage. Since this approach focuses on market activities, productivity losses are
not calculated beyond the age of retirement.
Under the human capital approach, assessing morbidity costs involves estimating lost
workdays attributable to HIV infection in 1998, and then applying an economic value, i.e.,
market wage rate, to these lost workdays. Mort lity cost measurement combines the number
of deaths caused by the HIV infection in 1998 and an economic value of each potential year of
life lost.  Notice that time horizon differs between morbidity and mortality cost assessment.
The former relates to work days lost during 1998 while the latter corresponds to the number of
potential years of life lost by HIV individuals deceased in 1998.  Since we assess future
potential earnings, the latter are discounted.
Discounting is the process of converting future earnings into their present value. A higher
discount rate signifies that future outcome is valued less than the immediate one, or in other
words, it reflects a higher preference for the present. The choice of the discount rate is a matter
of substantial debate. One differentiates between the social opportunity cost approach and the
social rate of time preference (Drummond et al. 1996). The former is based on the real rate of
return to society foregone in the private sector. The latter is a measure of society’s willingness
to forego consumption today in order to have greater consumption tomorrow. Interest rate on
a risk-free investment such as long term government bonds is commonly accepted as reflecting
social rate of time preference.
In practice, a rate of 5 % has commonly been used in health economics evaluations. Recent
official recommendations tend however to favour lower discount rates. For instance, the US
                                                 
55 S. Rosen, Human Capital, in: The New Palgrave: Social Economics, J. Eatwell, M. Milgate, P.
   Newman,MacMillan, 1990, Hong-Kong
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Public Health Service Panel on Cost-Effectiveness in Health and Medicine (Gold et al. 1996)
estimates that 3 % would be the most appropriate real discount rate for economic evaluation.
In our study, we consider a rate of 3 % as our baseline for discounting future potential
earnings. This rate reflects the rate of return on long term Confederation bonds. Alternative
discount rates of 0 % and 5 % are also applied to discount future potential earnings.
Another element to be taken into consideration when estimating future potential earnings is the
annual growth rate. The growth rate captures the notion of future productivity growth.
Since the human capital approach assumes that market wage rate reflects marginal
productivity, applying a growth rate to future earnings allows to account for future
productivity gains. We adopt a growth rate of 2 %, corresponding to the forecasted average
Gross Domestic Production (GDP) growth until 2005 by the Institute of Economic Research
(BAK), Basel.
5.2  MORBIDITY COSTS
Morbidity costs associated with HIV infection in Switzerland during 1998 are estimated for
permanent disability (full or partial) and temporary disability until the age of 64. Our main
source of information are the SHCS data and the Enquête Suisse sur la Population Active
(ESPA)56.
The SHCS data base provides information on patients’ income resources and working rates.
Data were analysed for 4’166 individuals. To assess lost productivity due to HIV infection, we
compare the working rate of SHCS patients with the corresponding rate in the general
population, and then value productivity losses using market wage. When comparing both
groups, labour force participation rates for different age groups and shifting patterns of earning
at successive ages are taken into consideration. We rely on the ESPA for data on general
population labour force participation and market wage. The median annual gross income of the
general population is displayed in Table 10.
Table 10: Median annual gross income: general population
Age Median annual gross income (full time)
46’000 Sfr.
15-24 65’000 Sfr.
25-39 74’000 Sfr.
40-54 75’400 Sfr.
55-69 40’500 Sfr.
Source: Enquête Suisse sur la Population Active (1998), Office Fédéral de la Statistique, Neuchâtel
                                                 
56 Office Fédéral de la Statistique (1999), Enquête Suisse sur la Population Active : Résultats Commentés et
   Tableaux, Neuchâtel
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The results obtained for SHCS patients are then extrapolated to the estimated 8’000 HIV
patients in Switzerland.  We assume that morbidity losses for HIV infected persons not
medically followed are similar to those of the general population.
On the average, the mean working rate of HIV infected individuals reached 50 % in 1998. By
comparison, this rate was around 70 % for the general population aged between age 20 and
64. Morbidity losses at Swiss level are depicted in Table 11. These results show that morbidity
costs are the most important within the age group 30-40 years old. The morbidity cost per
patient is estimated at 14’400 Sfr. (115’000’000 Sfr./8’000 patients). Details of the calculation
are displayed in Appendix 13.
Table 11: Morbidity lost market activities attributable to HIV infection, 1998
Age Morbidity losses at Swiss level
20-24                             1’290’000 Sfr.
25-29                           11’743’000 Sfr.
30-34                           30’203’000 Sfr.
35-39                           35’685’000 Sfr.
40-44                           19’800’000 Sfr.
45-49                            8’342’000 Sfr.
50-54                            3’132’000 Sfr.
55-59                            2’733’000 Sfr.
60-64                            2’172’000 Sfr.
TOTAL                         115’100’000 Sfr.
The figure of 115 million Sfr. illustrates the costs for a total number of 8’000 HIV patients in
Switzerland. If we consider a total number of patients of either 6’800 or 10’000 as in sub-
section 4.1.2.1, total morbidity costs would then amount to 97.9 million Sfr. or 144 million
Sfr., respectively.
5.3  MORTALITY COSTS
According to the SFOPH, AIDS caused 140 deaths in the 20-64 years old age group in
Switzerland during 1998. The corresponding number of potential years of life lost, depicted in
Table 12, amounts to 3'505. Deceased individuals are relatively young, the mean age at death
being 40 years.
Table 12: Potential life years lost between 25 and 64 years old, 1998
Age Number of death casesPotential life years lost
25-29 13 481
30-34 30 931
  49
35-39 45                 1’230
40-44 23 523
45-49 11 184
50-54 10 119
55-59  4   27
60-64  4  10
TOTAL                140                3’505
Based on a discount rate of 3 %, an annual growth of 2 %, and adjusting for labour force
participation, earning patterns and survival probability, the present value of total loss of future
production is estimated to be 160 million Sfr at the Swiss level, as shown in Table 13 (see
Appendix 14 for the details).  Since death occurs at a relatively young age, the average cost
per death is substantial.
Table 13: Mortality lost market activities attributable to HIV infection, 1998
Mortality Costs At Swiss level Average cost per death
Market losses               160’040’000 Sfr.                    1'143’000 Sfr.
Alternative discount rates of 0 % and 5 % were also examined. Mortality costs would reach
241.67 millions Sfr with a 0 % discount rate, whereas they would amount to 126.92 million
Sfr with a 5 % discount rate.
5.4 INDIRECT COSTS: SUMMARY AND DISCUSSION
In 1998, total indirect cost amounted to 275 million Sfr. in Switzerland, as depicted in Table
14. Under alternative scenarios, total indirect cost range from 225 million Sfr. to 385 million
Sfr. These scenarios rely either on other HIV patients figures or on different discount rates.
Table 14: Total morbidity and mortality lost market activities in Switzerland,
1998
Indirect Costs Lower Bound Scenario Main Scenario Higher bound
Scenario
 Morbidity costs
97’920’000 Sfr. 115’100’000 Sfr 144’000’000 Sfr.
Mortality costs 126’923’000 Sfr. 160’040’000 Sfr 241’166’000 Sfr.
Total Costs 224’843’000 Sfr. 275’140’000 Sfr. 385’166’000 Sfr.
Similarly to direct costs, HIV infection indirect costs per patient are significant. Morbidity cost
per patient is estimated at 14’400 Sfr. and the average cost per death at above 1 milli n Sfr.
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Hansvelt et al. (1994) estimated the average cost per death for HIV infection at 558'000 USD
in Canada (1 USD = 1.37 Sfr. 1994), a figure relatively close to ours. The young age of
deceased individuals contributes to the fact that average cost per death is quite substantial for
AIDS. Hansvelt et al., who also examined other causes of death such as ischaemic heart
diseases, suicide, motor vehicle accidents, and lung cancers, found that cost per death of all
these health conditions was lower than for AIDS.
As with direct costs, HIV indirect costs at  Swiss level are less important in comparison with
other public health concerns such as tobacco consumption and stress.  Indirect costs related to
tobacco consumption in Switzerland were estimated at 4’416 million Sfr  (Vitale et al. 1998).
This study included the measurement of lost non-market activities. Ramaciotti et Perriard
(2000) evaluated indirect costs of stress at 2’433 million Sfr. The scope of HIV indirect costs
tends to be similar to the one of asthma. Szucs et al. (1999) estimated asthma indirect costs in
Switzerland at 490 million Sfr.
Several methodological limitations should be noted in the context of our analysis. First, SHCS
data on working rates of persons living with HIV infection are self-reported data by SHCS
patients. Data on severely ill individuals unable to work and missing SHCS follow-up visits
because of their health state should therefore be missing. This may cause the actual working
rate of individuals living with HIV infection to be overestimated.
Second,  persons with HIV are assumed to have had the same earnings and labour force
participation rates as the overall Swiss population. This may however not be true since it has
been noted that, on the average, homosexual men who represent up to 35 % of HIV infected
individuals57, are likely to have higher average earnings58. On the other hand, other HIV
subpopulations such as injecting drug users may be expected to have lower than average
income profile. Whether these two effects counterbalance each other is not known.
Third, we also assume that persons living with HIV infection have had the same life
expectancy than the general population. Since many HIV patients tend to suffer from
co-morbidities such as chronic hepatitis C infection, (37 % of SHCS patients receiving
antiretroviral therapy are coinfected with chronic hepatitis C59) or have high risk
behaviours, (25 % are injecting drug users60),  mortality costs might therefore be
overestimated.
Fourth, our estimate was restricted to indirect costs associated with the lost value of market
output among individuals aged 25-64 years old. The human capital approach does not value
time not sold for a wage. In other words, skills utilised outside the market sector such as house
work, child education, care to family members etc. are not valued by the human capital
approach. The monetary assessment of these activities in Switzerland has been undertaken by
                                                 
57 P. Sudre et al. (2000), The Swiss HIV cohort study: Semi-annual report on recruitment and follow-up, SHCS
   Data Centre, Lausanne
58 Scitovsky A., Rice D. (1989), The cost of AIDS: an agenda for research, Health Policy vol. 11 : 197-208
59 Greub et al. (2000), Clinical progression, survival, and immune recovery during antiretroviral therapy in
    patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study, The Lancet, vol. 356 :
   1800-1805
60 P. Sudre et al. (2000), The Swiss HIV cohort study: Semi-annual report on recruitment and follow-up,
   SHCS Data Centre, Lausanne
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Schmid et al. (1999). They found that non market activities represented in 1997 between      38
% and 58 % of the Swiss Gross Domestic Product. Relying on the estimate of Schmid et al
(1999) gives a general sense of the losses associated with non-market activities. If we remain
conservative and assume that on the average non-market activities correspond to 38 % of
earnings, non-market activity would be estimated at 104,5 million Sfr. (morbidity and
mortality altogether) in Switzerland.  All in all, we consider our estimate of 275 million Sfr.
for indirect  costs related to HIV infection in Switzerland for the year 1998 as prudent  and
even conservative.
6  SUMMARY AND CONCLUSION
In this section we summarize our main points, and then we move on to a discussion of some
policy implications of our results.
The aim of Part I was to assess HIV social cost for the year 1998. The assessment of HIV
social cost in 1998 relied on a “Bottom-Up” model which reassembles the different
components of the social cost. Our evaluation of social cost focused on HIV direct and indirect
costs. Since methodologies for estimating intangible costs are quite complex to implement and
the results often difficult to interpret, particularly in a context of ongoing changes as is the case
for HIV, we have not included such costs in our study. Although we did not incorporate
prevention costs in the social cost, such costs were included in our study for comparison with
other cost categories.
We initially undertook a general overview of HIV epidemiology in Switzerland. HIV
epidemiology has significantly changed over the last years. The years 1995-1998 are
characterized by a decrease in new HIV and AIDS cases, and a decline in AIDS mortality. The
decline in new AIDS cases and AIDS mortality is clearly associated with the introduction of
HAART.
Our estimate of HIV prevention costs at the Swiss level in 1998 ranges from 41 to 62 million
Sfr., as illustrated in Table 15 summarising the different cost categories.  Despite the fact that
we concentrated only on the main prevention programmes, the above figures demonstrate that
HIV prevention expenses are quite substantial. On the basis of conservative assumptions, we
evaluated the cost of avoiding one HIV case at around 71’210 Sfr.
As for direct costs displayed in Table 16, one central result is the importance of
antiretroviral costs, e timated at 91 million Sfr., and accounting for more than  50 % of
total direct costs, evaluated at 168 million Sfr. This phenomenon illustrates a transfer
from inpatient to outpatient care. Prior to the introduction of HAART, hospital care
costs represented the main share of direct costs. For instance, they represented in 1993
up to 85 % of total direct costs in the Netherlands (Postma et al., 1995). HAART
introduction reversed this situation. We estimate that hospital care costs, in Switzerland,
represented 32 million Sfr. or 19 % of total HIV direct costs in 1998. Taken together,
HIV direct costs accounted for approximately 0.5 % of total Swiss health care costs. One
should not however conclude that HIV direct costs are unimportant. The annual cost
per patient, evaluated at 21’000 Sfr. in Switzerland, remains high.
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We furthermore examined indirect costs, i.e., morbidity and mortality costs, and adopted the
human capital approach to evaluate them. Both morbidity and mortality costs were assessed
for individuals until the age 64. Productivity losses associated with HIV morbidity were
estimated at 115 million Sfr. in 1998, whereas mortality costs were evaluated at 160 million
Sfr., as displayed in Table 16. It should be noted that our estimate is conservative since we
only considered losses resulting from market activities.
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 Table 15 : Prevention cost components (Sfr.)
COST COMPONENTS Lower Bound ScenarioMain scenario Higher Bound Scenario
Primary prevention   21’060’000 27’525’000       33’990’000
Secondary Prevention    19’972’000 25’453’000       28’423’000
 TOTAL PREVENTION COSTS   41’032’000 52’978’000       62’413’000
              Table 16 : Direct and indirect cost components (Sfr.)
COST COMPONENTS Lower Bound ScenarioMain scenario Higher Bound Scenario
   OUTPATIENT CARE
HIV related drug treatments   95’513’000      103’460’000         112’867’000
Medical and Para-Medial Care   23’478’000 28’130’000           37’018’000
   TOTAL OUTPATIENT CARE 118’991’000      131’590’000         149’885’000
   INPATIENT CARE
Hospital care   20’150’000 32'290’000           45’590’000
Institutional psycho-social care     3’440’000   4’300’000             5’160’000
   TOTAL INPATIENT CARE   23’590’000       36’590’000           50’750’000
   TOTAL DIRECT COSTS 142’581’000     168’180’000         200’635’000
   MORBIDITY COSTS    97’920’000     115’100’000         144’000’000
   MORTALITY COSTS  126’923’000     160’040’000         241’166’000
   TOTAL INDIRECT COSTS  224’843’000     275’140’000         385’166’000
   SOCIAL COSTS   367’424’000    443’310’000         586’301’000
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We estimate HIV social cost at 443 million  Sfr. (direct and indirect costs) in Switzerland for
the year 1998. Under alternative assumptions, reflecting either more or less conservative
views, social cost was estimated at 367and 586 million Sfr., respectively. We consider our
estimate of HIV social cost as reliable and even rather conservative.
The annual cost per patient is high, 21’000 Sfr. and 14’400 Sfr. for direct and morbidity costs,
respectively. In addition, since HIV infection affects relatively young people, average cost per
death due to AIDS is one of the highest among all causes of death.  HIV infection cannot
therefore be neglected within the frame of a public health policy. The success of prevention
during the last years contributed to decrease current HIV social costs. It may be noted that our
estimate of cost per avoided HIV case (71’210 Sfr.) corresponds approximately to 3.4 years of
inpatient/outpatient care costs. Thus nowadays avoiding a HIV case costs less than a lifetime
treatment of an infected patient. As mentioned, our estimate of prevention costs is rather
conservative. Therefore, we also assessed the cost per avoided HIV case, as displayed in Table
17, assuming larger HIV prevention budgets. We also do consider different effects of
prevention with regards to the decline of  new HIV infection cases. We adopted 1991 as our
baseline year because it corresponds to a peak in the number of new HIV infections in
Switzerland. There were, in 1991, 2144 new HIV infection cases and only 657 in 1998, i.e. a
decrease of 1’487 cases. We examine the hypotheses that between 10 % to 90 % of the
reduction in the number of HIV infection cases is attributable to prevention. For instance,
assuming that prevention is at the origin of 75 % of the 1’487 avoided cases, means that the
cost per avoided case amounts to 47’510 Sfr. under the hypothesis that prevention budget
totals 52.978 million Sfr., and to 95’020 Sfr., if we were to consider a prevention budget of
105.956 million Sfr.
Table 17: Cost per avoided HIV case
Decline in new HIV
infection cases
attributable to
prevention
Cost per avoided
HIV case
Budget 98:
52.978 million Sfr
Cost per avoided
HIV case
Budget 98: + 50 %
79.467 million Sfr.
Cost per avoided
HIV case
Budget 98: + 100 %
105.956 million Sfr.
Cost per avoided
HIV case
Vitali et al. (1997)
140 million Sfr.
  10  %   (149 cases) 355’560 Sfr. 533’340 Sfr. 711’110 Sfr. 939’600 Sfr.
  25 %   (372 cases) 142’410 Sfr. 213’620 Sfr. 284’820 Sfr. 376’340 Sfr.
  50 %   (744 cases)   71’210 Sfr. 106’820 Sfr. 142’420 Sfr. 188’170 Sfr.
    75 %  (1’115 cases)   47’510 Sfr.  71’270 Sfr.   95’020 Sfr. 125’560 Sfr.
     90%   (1’338 cases)  39’590 Sfr. 59’390 Sfr.   79’190 Sfr. 104’630 Sfr.
Figure 5 indicates after how many years the cost per avoided HIV case equates the annual
health care costs per patient. For instance, under the hypothesis that 90 % of the decline in
HIV cases is attributable to prevention and that the prevention budget reaches 52.98 million
Sfr., the cost per avoided HIV case would correspond to 1.9 years of health care treatment. In
contrast, assuming that only 10 % of the reduction in new HIV cases is the result of prevention
and that the prevention budget amounts to 140 million Sfr., the cost per case avoided would
equate annual health care costs after 44.8 years. One can notice that under the relatively
conservative assumption that prevention only contributes to 50 % of the decrease in the
number of new HIV infection cases, the break-even point is reached after 3.4 to 9 years.
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This makes prevention a cost-effective intervention, under the hypothesis that life expectancy
of a patient under treatment is longer than 10 years.
Figure 5: Yearly health care costs per patient and Cost per avoided HIV case
These results underline the importance of prevention and we strongly believe that prevention
should not be neglected as a tool to limit social cost. This is particularly true within the current
context suggesting a certain disregard of HIV prevention messages illustrated by the increase
in the number of sexual transmitted diseases like gonorrhoeae61. Similarly, recent studies
undertaken within the framework of the evaluation of the AIDS prevention strategy in
Switzerland show that high risk sexual behaviour has not further decreased, and has even
slightly risen among homosexuals (F. Dubois-Arber, personal communication, IUMSP,
Lausanne).
Another element emphasized by our study is related to the number of HIV infected individuals
not under antiretroviral drug treatment. Knowing that the number of HIV positive individuals
living in Switzerland is estimated at between 11’000 and 21’000 (SFOPH, 1999), and that we
evaluate the number of HIV treated patients at 6’100 in Switzerland, demonstrate that a
relatively important number of HIV infected individuals are not under antiretroviral drug
treatments. Our data and the framework of the study did not allow us to further investigate this
interesting public health issue. However, our estimate should be treated very carefully due to
the lack of data.
                                                 
61 Office Fédéral de la Santé Publique (2001), Déclaration de maladies infectieuses, Berne
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One should also take into account treatment recommendations. In 1998, the SFOPH62
recommended antiretroviral treatment for individuals with a CD4 cell count under 500 x 106/l.
Individual who do not fall in this category maintain a certain immunity and therefore do not
necessarily need to be treated. However, their number cannot explain the difference between
the total number of individuals living with HIV infection and the number of treated patients.
Further research should be undertaken in order to obtain more accurate figures and to
determine the reasons why a fraction of HIV positive individuals are not receiving
antiretroviral treatment. This question should be answered since it addresses the general issue
of access to health care.
                                                 
62 Office Fédéral de la Santé Publique (1998), Sous-commission clinique de la commission fédérale pour les
  problèmes liés au SIDA: Recommandations pour le traitement de l’infection à VIH en 1998, Bulletin OFSP,
  44 : 5-9
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PART II:
HIV SOCIAL COST: PROJECTIONS FOR 2001 & 2005
INTRODUCTION
In the previous chapters, we have established that the 1998 social cost (direct and indirect
costs) of the HIV disease amounted to 443 million Sfr.. We shall consider, in this second part,
future HIV social cost. The ongoing changes and progress over the last ten years demonstrate
that long term projections are hazardous, so we shall focus on a short time span and estimate
social cost for the years 2001 and 2005.
The future cost per patient and the demography of the HIV epidemic in the forthcoming years
are the two central elements for the determination of the future social cost of the disease. As
for the cost per patient, our projections are based on the current state of knowledge on HIV
infection. Therefore, the current HIV drug potency is assumed to remain unchanged in the
forthcoming years. To assess future development of the HIV epidemic in Switzerland, we rely
on the SHCS cohort. In particular, we hypothesize that the yearly number of new HIV
infection cases will remain similar to the level of 2000.
To project patients disease evolution, we rely on a mathematical model that describe  patients’
transition between different health states. To assess future social cost,  we estimate a cost
(direct and indirect) per unit of time for each health state, and multiply the latter by the
expected time spent by individuals in each health state. We apply our model to SHCS
individuals, and then extrapolate SHCS costs to the Swiss level.
 One can expect that both the future cost per patient and the demography of HIV epidemic will
affect future social cost. On the one hand, the cost per patient is likely to decrease in the
forthcoming years. This is because HIV patients are now benefiting from potent drugs such as
HAART, which decreases the reliance on hospitalisations. On the other hand, as a result of the
combined effect of HAART and of the yearly number of  ongoing new HIV infection cases, the
number of individuals living with the HIV infection will tend to grow over time, resulting in a
potential increase of the  social cost. Whether these two effects counterbalance each other is
what we shall examine in the following sections.
In the following, we first describe the mathematical model and then present, for each cost
component, the results of our projections. We begin our presentation with prevention, move
on with direct and indirect costs, and finally undertake a discussion of our results. In the
discussion, we address the possibility that major changes could take place in the treatment and
demography of HIV by the year 2005.
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1  THE MULTI-STATE MARKOV MODEL
To describe the HIV disease evolution over time, we consider a continuous time stationary
Markov model with five discrete health states.  In this model, individuals are at any time in one
of a finite set of states of health, and individuals move from state to state according to a set of
transition probabilities. Death is a particular state called “absorbing state”. The stationarity
assumption signifies that transition intensities do not depend on time, and therefore ageing
process is not taken into account, which holds true for relatively short time periods.
The model is depicted in Figure 6. Each transient health state is defined by a CD4 cell count
category corresponding to a clinical level of disease severity. Patients move from state to state
according to transition intensities ji,l  with i, j = 1..4, for the transient states, and im
with i = 1..4, for the absorbing state. Data about patients’ CD4 cell counts are provided by the
SHCS data base. The model, based on the SHCS data,  was estimated by the method of
maximum likelihood. This type of model is particularly useful for analysing data that are
irregularly spaced in time and that are strongly censored. Characteristics of the process such as
survival function, hazard function, waiting time in the different health states, and mean total
time spent in the health states were determined. A detailed presentation of the model, of the
results of the transition rates estimation, and of various functions is given in Appendix 15.
Figure 6: A Multi-State Markov Model of HIV Disease Evolution
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The estimated annual transition probabilities for SHCS cohort (treated or non treated)
between the different health states are presented in Table 18. The first column details the
different CD4 cell count categories. The transition probabilities are displayed in the third up to
the fifth columns. For instance, an hypothetical individual with a CD4 cell count above  500 x
106/l in the beginning of the year, has after one year a probability of 56.69 % to remain in the
same CD4 stratum, of 36.68 % to move to the 500-201 x 106/l CD4 category, of 5.7 % to be
in the 200-51 x 106/l CD4 category, of 0.45 % to be in the CD4 cell count category below 51 x
106/l, and 0.48 % to decease.
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An interesting result is that individuals have a greater probability to remain in the same CD4
stratum or to attain a superior one than to end up in a lower CD4 stratum.
Table 18: Transition matrix from 01.01.01 to 31.12.01
CD4 cell count
category
December 31st > 500 x 106/l 500-201 x 106/l 200-51 x 106/l < 51 x 106/l Death
January 1st
> 500 x 106/l 56.69 % 36.68 % 5.7 % 0.45 % 0.48 % 100 %
500-201 x 106/l 32.55 % 51.91 % 12.93 % 1.43 % 1.19 % 100 %
200-51 x 106/l  17.27 % 44.15 % 29.76 % 5.83 % 2.99 % 100 %
0-50 x 106/l   7.78 % 27.94 % 33.37 % 19.55 % 11.36 %100 %
Death        0 %          0 %        0 %      0 % 100 % 100 %
To make projections of future social cost, one must formulate hypotheses about the future
demographic evolution of the SHCS, that is, the annual number of patients joining the SHCS
(incident cohort cases), the survival of the prevalent cohort of 1998 and of incident cohort
cases, and finally the number of patients lost to follow-up who, consequently drop out of the
SHCS.
The number of incident cohort cases and lost to follow up is available in the SHCS data base
until the year 2000. For the year 2001, we assume that the number of incident cohort cases and
their CD4 structure at entry are the same as in 2000. Concerning patients lost to follow-up, we
hypothesize that the drop out process is at random, which holds approximately true for the
patients lost to follow-up in 2000, and that their number is the same as in 2000, i.e., 250
patients. The survival until January 1st,  2001 and beyond 2001 of the prevalent cohort of 1998
and incident cohort cases is determined, using our estimated Markov model. For the year
2005, we adopt the same approach and again consider the number of incident cohort cases to
be the same as in 2000 and the drop out process to be at random.
The expected number of patients in the different CD4 stratum on December 31st,  2001 and
2005 are depicted in Table 19. The following two elements from the results presented in Table
19 should be emphasized. First and foremost, the number of patients rises from 4’569 to 5’143
in 2001, and to 5’898 in 2005 (see Appendix 16 A and 16 B for the details). Second, CD4 cell
count of SHCS individuals increases.  The proportion of individuals in the CD4 stratum > 500
x 106/l rises from 26.6 % to 39.8 %. Furthermore, the proportion of individuals in low CD4
cell count categories tends to decrease. These results pertain to the potency of HAART. This
trend becomes less apparent when comparing the figures for 2001 and 2005.
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Note that the hypothesis of a constant number of incident cohort cases and of a similar CD4
cells distribution beyond 2000, as well as the stationarity assumption, all contribute to the fact
that the model converges quite rapidly to a steady state.
Table 19: Number of SHCS patients and CD4 distribution
CD4 cell count Patients
31.12.1998
PercentagePatients
31.12.2001
PercentagePatients
31.12.2005
Percentage
CD4 > 500 x 106/l 1’199 26.3 % 2’047 39.8 % 2’359 40.0 %
CD4 500-201 x 106/l 2’145 46.9 % 2’304 44.8 % 2’642 44.8 %
CD4 200-51 x 106/l 1’001 21.9 %     678 13.2 %    767 13.0 %
CD4 0-50 x 106/l   224  4.9 %    114 2.2 %   130   2.2 %
Total 4’569 100 % 5’143 100 % 5’898 100 %
Percentage change 1998-2001 + 13 % 2001-2005 +15 %
The number of deaths in the SHCS is expected to rise slightly, from 71 in 1998 to 77 in  2001,
and to reach 85 cases in 2005.
One can also represent the HIV epidemic characteristics in the near future as displayed in
Figure 7. This table shows the number of individuals in the different CD4 cell count categories
over time.
Figure 7: Number of individuals in the different CD4 cell count categories over time
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Finally, the model enables us to determine the mean time an individual will spend in each CD4
cell count category over a one year time period. Results are displayed in Table 20 (see
Appendix 17 for a detailed presentation). For instance, an hypothetical individual, with a CD4
cell count above  500 x 106/l at the beginning of the year will spend on the average 8.8 months
in the corresponding stratum, 2.86 months in 500-201 x 106/l stratum, .3 month in the 200-51
x 106/l stratum, and only 0.02 month in the lowest stratum, i.e., 0-50 x 106/l.
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Since the death probability of an individual is non-zero, the expected mean time spent in the
death state is, in this example, 0.02 month.
Table 20 : Mean time spent in each health state during one year  (months)
CD4 cell count
category
December 31st > 500 x 106/l 500-201 x 106/l 200-51 x 106/l < 51 x 106/l Death Total
Months
January 1st
> 500 x 106/l 8.8 2.86 0.3 0.02 0.02 12
500-201 x 106/l 2.54 8.19 1.13 0.08 0.06 12
200-51 x 106/l 0.91 3.85 6.44 0.62 0.18 12
0-50 x 106/l 0.31 1.62 3.55 5.68 0.84 12
Our final remark concerns the intrinsic limitations of the multi-state Markov model that we
adopted. First, the memoryless Markovian assumption means that two individuals in the same
CD4 cell count category face the same transition probabilities whatever their previous history
was. This assumption does not reflect all the medical complexity of the HIV disease. Second,
the stationary assumption which holds true for relatively short time periods would lead to a
serious bias in a long term study.
Below, we present our projections for the future social cost. Based on the same classification
as in Part I, we review each social cost component. For each component, we first evaluate a
unit time cost associated with each health state, i.e., CD4 cell count category. To perform the
projections, we then combine the unit time cost with the expected number of individuals in
each health state as estimated by the multi-state Markov model.
2  PREVENTION COSTS
We consider public prevention expenses as a public health policy decision and assume that
prevention costs, in the forthcoming years, will remain stable, lying between 53 million Sfr.
and 64 million Sfr. These figures represent the s andard scenario and the higher bound limit of
estimated prevention costs for 1998.
3  DIRECT COSTS
In this section, we detail how we estimate the health care costs associated with each CD4 cell
count category and present the results of the projections for the year 2001 and 2005. We begin
with antiretroviral drug costs, followed by ambulatory and hospital care costs. Such an
approach allows to differentiate costs according to health states. However, we shall observe
that for antiretroviral drugs (the main direct cost component), the cost per patient is
independent of the health state. As for the remaining direct cost components, i.e., co-morbidity
drugs, co-medication, psychotherapy and institutional psycho-social care, it was impossible to
perform a cost stratification by CD4 cell count category due to the lack of data. Therefore, an
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average cost was calculated for the these cost components grouped under the denomination
“other direct costs”.
3.1 ANTIRETROVIRAL DRUG COSTS
We differentiate between two antiretroviral drug categories, HAART (3 or more
antiretrovirals) and bi-therapy ( 2 antiretrovirals). Antiretroviral drugs constitute a particular
case since dosage is independent of CD4 cell count. In other words, annual mean treatment
cost, depicted in Table 21, for HAART and bi-therapy,  is similar, whatever the CD4 stratum.
To derive the mean annual treatment cost, we combined standard daily dose of antiretroviral
drugs and the corresponding cost per day.
Table 21: Annual mean treatment cost per patient
Treatment Annual Mean Treatment Cost
HAART 17’000 Sfr.
  Bi-therapy 11'000 Sfr.
One should also account for the proportion of individuals treated in each CD4 stratum. The
SHCS data do not show any significant differences of treatment distribution between CD4
strata. On a yearly basis and within each CD4 stratum,  around 70 % of SHCS patients were
receiving HAART in 1998, 10 %  bi-therapy and 20 %63 no treatment at all. We assume that
these proportions and the annual mean treatment cost per patient will remain unchanged.
The expected antiretroviral drug cost for the year 2001 and 2005 is obtained by combining
annual mean treatment cost and the expected number of individuals under each treatment in
2001 and 2005.  This amount, representing the SHCS antiretroviral drug costs, is then
extrapolated to the Swiss level. Since SHCS antiretroviral drug costs represented around 65 %
of Swiss antiretroviral costs in 1998, we adopt the same ratio for the year 2001 and 200564.
The results are presented in Table 22. The second column displays the actual cost at the Swiss
level in 1998. Projections of future antiretroviral drug costs are presented in the third and
fourth column, respectively. Antiretroviral drug costs increase by approximately 4 % a year, as
a result of the rise in the number of treated patients.
                                                 
63 This percentage consist of patients who are not treated at all and of patients having treatment
interruptions.
64 In appendix 18, we display the ratios comparing SHCS costs and costs at the Swiss level.
These ratios are used to extrapolate the different SHCS cost components  to the Swiss level.
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Table 22: Total antiretroviral drug costs at the Swiss level
Costs at the Swiss level 1998 2001 2005
Antiretroviral drug costs 91’400’000 Sfr. 102’882’000 Sfr. 117’986’000 Sfr.
Percentage change       1998-2001:  + 13
%
       2001-2005:  + 15 %
A change in the price of antiretroviral drugs would have a significant effect on our projections
since they represent the main direct cost component. For instance, if we were to consider a
hypothetical policy aiming at controlling total antiretroviral drug expenses in Switzerland,
establishing that  total antiretroviral drug expenses could not exceed the amount attained in
1998, i.e., 91.4 million Sfr., this policy would require a reduction of 11 % of antiretroviral
drugs prices by the year 2001 and of 23 % by the year 2005. These price reductions would
allow a decrease of the social cost of 11.5 million Sfr in 2001  and 26.6 million Sfr in 2005,
respectively.
3.2 AMBULATORY MEDICAL VISIT COSTS
In this sub-section, we first evaluate ambulatory medical costs according to CD4 cell count
categories, and then present the results of the projections for the year 2001 and 2005.
The ambulatory medical visit cost stratification relies on the annual mean number of medical
visits per patient, stratified by CD4 stratum, and the average cost per medical visit. The
estimate of the number of annual medical visits stratified by CD4 stratum was derived from
HIV positive outpatients (CHUV and private practitioners who collaborated with our study),
representing altogether around 450 patients. The CD4 cell count closest to the medical visit
date was used. The annual mean number of visits, depicted in Table 23, ranges from 6 to 12.
We notice that the number of visits is quite similar with the exception of individuals with low
CD4 cell counts. The average cost of a medical visits was estimated at 400 Sfr. Multiplying the
average cost of a medical visit  by the annual number of medical visit per patientgives the
annual mean medical visit cost per patient, as illustrated in Table 23.
Table 23: Annual mean medical cost per patient according CD4 count level
CD4 cell count categoryAnnual number of medical
visits per patient
Annual mean
medical visit costs
CD4 >500 x 106/l   6 2’400
CD4 201-500 x 106/l   7 2’800
CD4 51-200 x 106/l   9 3’600
CD4 0-50 x 106/l 12 4’800
Future social cost is obtained by combining the annual mean medical visit costs stratified by
CD4 cell count category, the number of expected individuals in 2001 and 2005, and the
expected time spent in each CD4 stratum by these individuals. The amount, corresponding to
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future SHCS ambulatory medical visit costs, is then extrapolated to the Swiss level.  Total
ambulatory medical visit costs at the Swiss level for the years 2001 and 2005 are displayed in
the third and fourth column of Table 24, respectively.
Table 24: Total ambulatory medical visit costs at the Swiss level
Costs at the Swiss level 1998 2001 2005
Ambulatory medical visit costs24’000’000 Sfr.  26’089’000 Sfr. 29’843’000 Sfr.
Percentage change        1998-2001:  + 9 %          2001-2005:  +14 %
The annual ambulatory medical cost per patient is expected to decrease, as a result of an
average increase in CD4 cells, from 3000 Sfr. in 1998 to approximately 2’800 Sfr in 2005.
However, due to the additional number of expected patients in the forthcoming years, total
ambulatory medical costs are expected to further increase within the next years as shown in
Table 24.
3.3 HOSPITAL CARE COSTS
In this sub-section, we first estimate an expected hospital care cost stratified by CD4 stratum,
and then present the outcome of our projections for the years 2001 and 2005.
We obtain the expected hospital care cost by multiplying hospitalisation rate associated with
each CD4 stratum by the corresponding hospital care costs. Hospitalisation rates, derived from
SHCS data, are significantly higher for individuals with low CD4 cells, as illustrated in Table
25.
To stratify hospital care costs by CD4 stratum, we matched cost per hospitalisation with the
CD4 cell count closest to time of hospitalisation. This procedure was undertaken for
approximately 100 HIV patients hospitalised in the CHUV in 1998. The expected hospital care
costs are displayed in the fourth column of Table 25. One can note that low CD4 level count
categories are associated with high hospital care costs.
Table 25: Expected hospitalisation cost stratified by CD4 cell count categories
CD4 cell count categoryHospitalisation rate
(1)
Cost per
Hospitalisation
(2)
Expected hospitalisation
cost per patient
(1)*(2)
CD4 >500 x 106/l 23 % 6’000 Sfr. 1’380 Sfr.
CD4 201-500 x 106/l 24 % 10’800 Sfr. 2’590 Sfr.
CD4 51-200 x 106/l 39 % 17’100 Sfr. 6’670 Sfr.
CD4 0-50  x 106/l 69 % 27’000 Sfr. 18’630 Sfr.
One should note some methodological limitations of our approach. Hospitalisation data used to
estimate the cost per CD4 cell count category are self-reported by SHCS patients. Therefore,
data on patients shortly deceased after being hospitalised might not be recorded in the SHCS
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data base, and hence hospitalisation rates could be underestimated. On the other hand, since
the SHCS data indicate whether or not an individual was hospitalised within the last six
months,  but do not provide information on the number of hospitalisations within that time
period, hospitalisation rates might be underestimated. Whether these two effects
counterbalance each other is unclear.
Total hospital care costs for 1998, 2001 and 2005 at the Swiss level are displayed in Table 26.
In the short run, hospital care costs are slightly declining. The cost per hospitalisation
decreases from 12’700 Sfr. in 1998 to 11’500 Sfr. in 2001. This is explained by the expected
health improvement of HIV patients. However, the decreasing trend in total hospital care costs
should be offset by a rise in the  number of HIV patients over the next years. Total hospital
care costs is expected to increase by 13 % between 2001 and 2005.
Table 26: Total hospital care costs
Costs at the Swiss level 1998 2001 2005
Hospital care costs 32’290’000  Sfr. 31’390’000 Sfr. 35’418’000 Sfr.
Percentage change       1998-2001:  - 3 %        2001-2005:  + 13 %
Different elements could contribute to a different evolution in hospital care costs. One major
issue is the magnitude and importance of treatment side-effects. So far, few cases of treatment
side-effects are reported. It is estimated that they account for approximately 2 % of
hospitalisations in the CHUV (A. Telenti, CHUV, personal communication). However, one
might not exclude that this could change in the near future. For instance, under the hypothesis
that the cost per hospitalisation for side-effects is similar to the average cost per
hospitalisation, an increase in the number of hospitalisations of 3 % by 2001 due to treatment
side-effects, assuming that side-effects hospital care costs are equal to the average
hospitalisation, would be enough to outweigh the expected hospital care costs decline between
1998 and 2001.
3.4  OTHER DIRECT COSTS
An average cost, evaluated at 2’561 Sfr., was calculated for the “other direct costs” category.
This amount was derived by adding up each “other direct cost” component that we estimated
in Part I, and dividing the sum by the estimated 8000 HIV patients medically followed in
Switzerland.  
The results for the years 1998, 2001 and 2005 are displayed in Table 27. Total “other direct
costs” are expected to increase as a result of the growing number of HIV patients.
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Table 27 :Total “other direct” costs
Costs at the Swiss level 1998 2001 2005
Other direct costs 20’490’000 Sfr. 23’065’000 Sfr. 26’451’000 Sfr.
Percentage change        1998-2001:  + 13 %       2001-2005:  + 15 %
4  INDIRECT COSTS
In this section, we examine future morbidity and mortality costs.  We initially examine
morbidity costs and then mortality costs. For the former, we first detail our assessment of costs
stratified by CD4 stratum before displaying our forecasts for the years 2001 and 2005.  For the
latter, we consider an average cost per AIDS death that was estimated in section 5.2 in Part I.
4.1 MORBIDITY
In order to stratify morbidity costs by CD4 level cell count categories, we differentiate working
rate according to CD4 stratum and place an economic value on productivity losses using wage
rate. Our main source of information are the SHCS data and the “Enquête Suisse sur la
population active” (ESPA). The SHCS data base provides information on working rate of HIV
patients. The latter, displayed in Table 28, is then compared to the working rate of 38 years old
individuals – the mean age of SHCS patients - of the general population. Relying on ESPA
data, the working rate of 38 years old individuals is 71 %.  The difference between the
working rate of HIV patients and of the corresponding general population is displayed in the
third column and represents the productivity loss associated with HIV infection.
We used the number of 65’000 Sfr., corresponding to the median annual gross income of
individuals of 38 years according to the ESPA, to value productivity losses. Annual
productivity losses, illustrated in the fourth column, range between 9’750 Sfr. and 26’000 Sfr.
Table 28 : Productivity loss associated with HIV infection
CD4 cell count category Working rate of HIV
patient
Working rate
difference with the
general population
Annual Productivity
Loss
CD4 >500 x 106/l 55 % - 16 %  10’400
CD4  201-500 x 106/l 50 % - 21% 13’650
CD4  51-200 x 106/l 40 % - 31 % 20’150
CD4  0-50 x 106/l 30 % - 41 % 26’650
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Since we rely on SHCS data to stratify morbidity costs, one might expect that individuals
severely ill and unable to work, i.e., with low CD4 levels, do not attend follow-up visits, and
hence may cause the working rate of individuals with low CD4 levels to be overestimated.
The results of the projections of morbidity costs at the Swiss level indicate that morbidity costs
per patient decreases over time, from 14’200 Sfr. in 1998 to 13’400 Sfr. in 2005. This is
explained by the rise in the number of individuals in superior CD4 strata over time. However,
this effect is offset over time by the increase in the number of HIV patients as displayed in
Table 29. All in all, morbidity costs are expected to slightly rise, at a annual rate of
approximately 3 % per year.
Table 29 : Total morbidity costs at Swiss level
Costs at the Swiss level 1998 2001 2005
Morbidity costs  115’090’000 Sfr.     122’714’000 Sfr.     140’157’000 Sfr.
Percentage change      1998-2001:  + 7 %    2001-2005:  + 14 %
4.2 MORTALITY COSTS
Finally, we examine mortality costs. In order to assess future mortality costs, we multiply the
average cost per AIDS death, estimated at 1.1 million Sfr. in sub-section 5.3 in Part I,  by the
number of expected deaths caused by AIDS in 2001 and 2005. Since the expected number of
deaths is expected to rise slightly from 140 in 1998 to 168 in 2005, mortality costs increases as
well. The results are presented in Table 30.
The mortality rate is relatively stable and is estimated at around 1.5 %. The rise in the number
of AIDS deaths stems from the increase in the number of HIV patients.
Table 30 : Mortality costs at the Swiss level
Costs at the Swiss level 1998 2001 2005
Mortality costs 160’040’000 Sfr. 173’564’000 Sfr. 191’597’000 Sfr.
Percentage change        1998-2001:  + 8 %      2001-2005:  + 10 %
Number of deaths 140 152 168
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5  SUMMARY AND CONCLUSION
HIV social cost in the forthcoming years is characterised by two opposite trends. On the one
hand, as a result of an expected average improvement in the health state (CD4 cells) of
individuals living with HIV infection, the direct and morbidity cost per patient will decline.  On
the other hand, the number of individuals living with HIV infection will increase, even under
the hypothesis of a constant number of incident cohort cases. On the basis of our hypotheses,
the rise in the social cost generated by the demographic evolution of the HIV epidemic should
outweigh the downwards trend in the social cost associated with the decline in the cost per
patient.  All in all, HIV social cost is expected to increase in the forthcoming years.
The results at the Swiss level for the different components of the social cost are presented in
Table 31. The social cost for the year 1998, derived from the “Bottom-Up” model, is displayed
in the second column. The third and the fourth column indicate the forecasted social cost for
the years 2001 and 2005. HIV social cost is expected to rise, from 443 million Sfr. in 1998 to
541 million Sfr. in 2005, corresponding to an annual total increase of approximately
3 %.   
Table 31: HIV social cost at the Swiss level
Cost category 1998 2001 2005
ART costs   91’400’000 Sfr. 102’882’000 Sfr. 117’986’000 Sfr.
Ambulatory costs   24’000’000 Sfr.  26’089’000 Sfr.  29’843’000 Sfr.
Hospital care costs   32’290’000 Sfr.  31'389’000 Sfr.  35’418’000 Sfr.
Other direct costs   20’490’000 Sfr.   23’065’000 Sfr.   26’451’000 Sfr.
Total Direct Costs 168’180’000 Sfr. 183’425’000 Sfr. 209’698’000 Sfr.
Morbidity Costs 115’090’000 Sfr. 122’714’000 Sfr. 140’157’000 Sfr.
Mortality Costs 160’040’000 Sfr. 173’565’000 Sfr. 191’597’000 Sfr
Total Indirect Costs 275’130’000 Sfr. 296’279’000 Sfr. 331’754’000 Sfr.
Total Costs 443’310’000 Sfr. 479’704’000 Sfr. 541’452’000 Sfr.
Percentage change        1998-2001 :  + 8 %        2001-2005 :  13 %
Total number of
patients
medically followed
8’000 9’010 10’330
Different elements, however, could modify these conclusions. First, a change in the price of
antiretroviral drugs would have a significant effect on social cost since they represent the main
direct cost component. Some pharmaceutical companies have announced significant price
reductions of antiretroviral drugs for developing countries. Obviously, one cannot  expect such
reductions in developed countries, but the projected increase of antiretroviral drug costs in the
near future represent an argument in favour of a policy aimed at controlling antiretroviral drug
expenses in Switzerland.
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We demonstrated that with a policy maintaining total antiretroviral drug expenses in
Switzerland at the level of 1998, i.e., 91.4 million Sfr., the price of antiretroviral drugs would
have to decrease by 11 % by the year 2001 and of 23 % by the year 2005. Under this
hypothesis, social cost would reach, ceteris paribus, 468 million Sfr. in 2001 and 515 million
Sfr. in 2005 as illustrated in Figure 8. If we were to further maintain the social cost of 1998,
i.e., 446.6 million Sfr., this would mean a decrease of then antiretroviral drug price of 35 % by
2001 and of 83 % by 2005. In the current context, such examples are only hypothetical, but are
good examples of the potential impact of a price reduction of antiretroviral drugs.
Second, new therapeutic options could be developed in a near future, namely intermittent
antiretroviral drug treatments (Hirschel et al. 2001). Assuming that treatment discontinuation
will become common practice in the near future, it will lead to a decrease of total antiretroviral
drug costs, depending on the number of patients meeting the criteria. In addition, treatment
discontinuations might reduce the frequency of drug side-effects.
Figure 8 : Future social cost : Different scenarios
4 0 0  0 0 0  0 0 0
4 4 0  0 0 0  0 0 0
4 8 0  0 0 0  0 0 0
5 2 0  0 0 0  0 0 0
5 6 0  0 0 0  0 0 0
1998 1999 2000 2001 2002 2003 2004 2005
S t a n d a r d  s c e n a r io
L im i ted  A R T  e x p e n s e s   
( leve l  o f  98)
H o s p i t a l i s a t i o n  I n c r e a s e  
Third, an increase in the number of hospitalisations due to treatment side-effects/toxicity would
also affect our projections. The introduction of HAART was followed by a decrease in the
number of hospitalisations. However, one cannot exclude that the number of toxicity/side-
effects treatments might increase in the forthcoming years. We demonstrated that a small
increase in hospitalisation rate would outweigh the expected decline in hospitalisation cost
between 1998 and 2001. Under the hypothesis that the number of hospitalisations due to
treatment side-effects/toxicity would substantially rise, resulting in a 10 % growth in the
number of hospitalisations, social cost would reach, ceteris paribus,  483 mill on Sfr. in 2001
and 545 million Sfr. in. 2005.  As shown in Figure 7, the impact on social cost is small, but
could be greater if we also consider that more frequent hospitalisations could lead to a rise in
morbidity and mortality.
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Fourth, a change in the number of deaths in the forthcoming years would have an impact on
social cost. On the basis of the epidemiological trend of the last years, one could expect that
the number of deaths could either become stable or even further decrease. If we were to
assume that the number of deaths, in the forthcoming years, would be similar to the level of
1998, i.e., 140 cases, total social cost would reach 466 million Sfr. in 2001 and 510 million in
2005. In order to maintain the social cost of 1998, i.e., 443 million Sfr., the number of deaths
should reach in 2001 120 cases, instead of the expected figure of 152, and 82 cases in 2005
rather than the expected 168 cases. The actual impact of a decline in the number of AIDS
deaths might even be greater, since we did not account for the potential decrease in health care
and morbidity costs associated with a lower mortality rate.
Finally, a substantial change pertaining to the future number of yearly new HIV infection cases
would have an impact on future social cost. We implicitly assumed that the future yearly
number of new HIV infection cases would remain similar to the present level. However, a
certain disregard of prevention messages as mentioned in Part I, section 6, could suggest that
the number of new HIV cases could increase over the next few years. In that case, we would
have underestimated future social cost. On the other hand, a further decline in the number of
new HIV cases would result in a lower social cost.
The above elements lead us to consider the role of prevention in the forthcoming years. The
decline in the number of new HIV infection cases over the last years and the relatively small
share represented by HIV in the Swiss health care costs could suggest that HIV prevention
might become less important in the future. Our projections suggest, on the contrary, that HIV
prevention should remain a key element in the battle against HIV since our projections show
that the social cost is expected to rise in the forthcoming years. In that context, prevention
constitutes an essential means to limit or reduce the HIV social cost over the next years.
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